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Abstract 
Background and aims. Aplastic anemia (AA) is a rare but life-threatening 
disease. The introduction of immunosuppressive treatment (IST) and 
hematopoietic stem cell transplantation (HSCT) has considerably improved the 
outcome of patients with AA. However, modern-day population-based data are 
limited. This thesis aimed to retrospectively analyze the incidence, treatment 
modalities, survival, and immune markers in the bone marrow of patients 
diagnosed with AA in Sweden from 2000–2011.  
Patients and methods. Patients were included via the National Patient 
Registry and diagnosed according to the Camitta criteria. All data were 
collected from medical charts. In paper IV, immunohistochemistry was used 
to obtain data on regulatory T cells and macrophages in the bone marrow. 
Results and conclusions. We identified 257 confirmed cases, with an overall 
incidence of 2.35 cases per million inhabitants per year. The 5-year overall 
survival (OS) was >90% in patients aged up to 39 years but 38.1% in patients 
aged ≥60 years. Multivariate analysis showed that age ≥40 years, very severe 
AA, and no specific therapy were independent risk factors for inferior survival. 
First-line IST treated patients (n=158) showed a 47% response rate with no 
difference regarding the age groups or anti-thymocyte globulin (ATG) 
formulation. The response was significantly associated with the severity grade 
at the time of treatment initiation, and very severe AA patients exhibited a 
response rate of 22%. Sixty-eight patients underwent HSCT with a 5-year OS 
of 86.8%. The graft-versus-host-disease-free, relapse/rejection-free survival at 
5 years was 69.1%. Patients aged ³40 years had higher transplant-related 
mortality that translated into a lower 5-year OS. In paper IV, we found lower 
numbers of FOXP3-positive regulatory T cells in AA patients without 
predictive value for IST response and that patients with a higher number of 
CD163-positive macrophages had a better 5-year OS, but this benefit was only 
observed in the non-severe AA group. In conclusion, younger patients have 
very good long-term survival regardless of the choice of therapy, whereas the 
outcome for patients ≥60 years remains poor. Very severe AA patients respond 
poorly to ATG, which indicates the need for a different treatment approach. 
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Sammanfattning på svenska 
Aplastisk anemi (AA) är en sällsynt men mycket allvarlig blodsjukdom. Den 
orsakar låga blodvärden och cellfattig benmärg. AA har i de flesta fall en 
autoimmun orsak och svarar ofta på immunhämmande behandling (IST) med 
antithymocytglobulin (ATG). Sjukdomen har olika svårighetsgrader, som 
beror på nivån av vita blodkroppar i blodet. Man har kunnat påvisa en minskad 
förekomst av regulatoriska T-celler (Tregs) och ökad förekomst av makrofager 
hos AA-patienter. Vi har retrospektivt studerat incidens, överlevnad, 
behandlingsregimer och immunologiska markörer i ett stort 
befolkningsbaserat, oselekterat patientmaterial med AA som insjuknade i 
Sverige under åren 2000-2011. Vi observerade att incidensen på AA inte har 
ändrat sig de senaste 30 åren: i Sverige insjuknar 2,35 personer per miljon 
invånare och år. Vi identifierade sammanlagt 257 AA patienter med en 
medianålder på 60 år. Primär behandling i form av IST gavs till 63%, 10% 
benmärgstransplanterades, och 27% fick palliativ eller ingen behandling alls. 
Vi såg att 5-års-överlevnaden tydligt påverkades av ålder och att ålder >40 år, 
mycket svår AA (VSAA) och palliativ behandling/ingen behandling alls var 
oberoende riskfaktorer för sämre överlevnad. Vidare har vi analyserat 
behandling med ATG (n=158) och sett att knappt 50% svarar på sådan 
behandling. Behandlingssvaret var tydligt beroende av svårighetsgraden: 
patienter med VSAA svarade sämst. Benmärgstransplanterade patienter 
(n=68) hade en 5-års-överlevnad på 86,8% och överlevnaden påverkades av 
patienternas ålder: 92% för patienter <40 år och 71% för patienter ³40. 
Transplantat-mot-mottagare sjukdom (GvHD) kan vara en mycket allvarlig 
komplikation efter transplantation. Vi analyserade därför det nya kombinerade 
utfallsmåttet GvHD och avstötning/återfallsfri överlevnad (GRFS) vilket 
tidigare inte gjorts vid aplastisk anemi och såg en 5-års-GRFS på 69%. 
Patienter över 40 år hade en sämre GRFS (53%). Till slut analyserade vi 
immunmarkörer (Tregs och makrofager) i benmärgen på AA patienter och 
friska kontroller. Vi fann mycket låga Tregs hos AA patienter utan samband 
med behandlingssvar. Samtidigt såg vi att patienter med högre antal 
makrofager hade bättre överlevnad, i synnerhet icke-svåra AA patienter. 
Vi kan konkludera att unga patienter klarar sig bra, oavsett primär behandling 
och att den största utmaningen idag är förbättra behandlingen för lite äldre 
patienter och patienter med mycket svår aplastisk anemi. 
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Definitions in short 
Severe AA 
 
 
Bone marrow cellularity <25%, or 25%-
50% with <30% residual hematopoietic 
cells and 2/3 of the following: neutrophil 
count <0.5×109/l; platelet count 
<20×109/l; reticulocyte count <20×109/l 
(Camitta, 1975) 
Very severe AA As for severe AA but neutrophils 
<0.2×109/l (Bacigalupo 1988). 
Non-severe AA Not fulfilling the criteria for severe or 
very severe aplastic anemia (Camitta, 
1975) 
Complete remission Hemoglobin normal for age; neutrophil 
count >1.5×109/l; platelet count 
>150×109/l (Camitta, 2000) 
Partial remission Transfusion independent, no longer 
meeting criteria for severe disease 
(Camitta, 2000) 
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1 Introduction 
Aplastic anemia (AA) is a rare and potentially lethal disease. It is 
characterized by empty bone marrow and pancytopenia. More than 100 
years ago (1888), Paul Ehrlich described the autopsy of a young woman 
who had a short fatal illness characterized by anemia, bleeding, and 
infection accompanied by yellow instead of red bone marrow in her 
femur1. The disease was first named pernicious to reflect its fatal course. 
In 1904, Vaquez and Aubertin described another fatal case in which 
histological examination revealed fatty bone marrow with few 
lymphocytes, and the term AA was used for the first time2. Clinical 
disease features were described by Richard C. Cabot and other 
pathologists in the early 20th century3. Factors responsible for AA 
development have changed over time. At the beginning of the 1900s, the 
industrial exposure of benzene and subsequent development of AA were 
reported among Swedish bicycle factory workers and Newark (USA)  
leatherworkers4,5. In the 1960s, several AA patients were diagnosed 
during the introduction of chloramphenicol,6,7 and the direct toxic effect 
was assumed to be responsible for the occurrence of AA. Since the 
1970s, after the first bone marrow transplantation and the use of anti-
lymphocyte globulin (ATG) to treat AA, evolving evidence for a 
possible immunological mechanism contributing to AA has been 
reported. Today, immunological bone marrow destruction is considered 
the main underlying mechanism in AA. 
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1.1 Definition and diagnostic criteria 
AA is sometimes referred to as idiopathic, acquired, or immune. It is 
defined as pancytopenia with hypocellular bone marrow in the absence 
of fibrosis or an abnormal infiltrate. For the diagnosis of AA, at least 
two of the three following criteria must be present: hemoglobin <100 
g/l, platelet count <50×109/l, or neutrophil count <1.5×109/l8,9.   
To assess AA severity, modified Camitta criteria are used8,10: 
Severe AA (SAA) is defined as bone marrow cellularity <25% or 25%–
50% with <30% residual hematopoietic cells and two of the following 
three criteria: neutrophil count <0.5×109/l, platelet count <20×109/l, or 
reticulocyte count <20×109/l. Very severe AA (VSAA) is similar to 
SAA but with a neutrophil count <0.2×109/l. Non-severe AA (NSAA) 
does not fulfill the criteria for SAA or VSAA. 
 
1.2 Epidemiology  
The incidence of AA varies considerably in different parts of the world 
and has also changed over the years. Historically, reports from Europe 
and the United States in 1960–70 showed diverse results; incidence rates 
of up to 6–10 AA cases per million people per year. In some of these 
studies, an association with toxic agriculture substances was shown11-13. 
However, different diagnostic criteria were used, and some cases 
represented other diagnoses11. The International Agranulocytosis and 
Aplastic Anemia Study (IAAS) involving several regions in Europe and 
Israel was published in 1987 and established a well-accepted AA 
incidence of ~2 cases per million people per year9. Several other studies 
from the UK14, France15, Spain16, and Brazil17 have shown similar 
results. However, recent studies from Asia show a much higher 
incidence of up to 7 cases per million people per year,18-22 which are 
mostly associated with agricultural substances19,21. It is also well known 
that the incidence of AA has two peaks, one between 15–30 years of age 
and another after 60 years of age15,16. The incidence for men and women 
appears to be similar but has been reported to be slightly higher among 
women in some studies9,14. 
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1.3 Pathophysiology 
Most cases of AA can be pathophysiologically characterized by the T 
cell-mediated destruction of bone marrow hematopoietic cells23. 
However, hematopoietic failure can also result from direct physical or 
chemical damage to the marrow. Radiation and cytostatic drugs used to 
treat cancer often cause aplasia in the bone marrow, but other treatments, 
such as nonsteroidal anti-inflammatory drugs, antibiotics 
(sulfonamides), antithyroid drugs, antiepileptics, psychotropics, gold, 
penicillamine, and allopurinol, have also been associated with AA 
development24,25. Childhood AA may follow viral exposure. For 
example, the Epstein-Barr virus and seronegative hepatitis can cause 
SAA26,27, likely by activating the immune system. In addition, other 
immunological conditions, such as eosinophilic fasciitis28, thymoma,29 
and Graft-versus-Host disease (GvHD)30, can be complicated with AA. 
 
1.3.1 Immunological mechanisms 
The idea that immunological mechanisms are responsible for the 
development of AA was assumed many years ago (1960–1970s) based 
on the first bone marrow transplantation results. The conditioning 
regimen with an anti-lymphocytic serum that enhanced the 
transplantation results (reduced acute secondary disease)31 and failed 
attempts of the syngeneic transplants without conditioning showed that 
the substitution of bone marrow/stem cells alone could not repopulate 
the bone marrow32. Even if some immunological mechanisms 
contributing to the development of AA have been identified, the 
responsiveness to immunosuppressive treatment (IST) remains the most 
convincing evidence of an underlying immune pathophysiology33. 
Already in the 1990s, a deficit of early progenitor cells was found, 
proposing that less than 10% of healthy stem cells are left at the time of 
the clinical presentation of AA23,34. Moreover, research has focused on 
cytotoxic T cells, which appear to be functionally and phenotypically 
activated35-40, producing interferon-γ	 (IFN-γ)41,42 and stimulating 
apoptosis through the Fas/Fas ligand pathway3,43. Recently, it was 
Aplastic anemia - a population-based study of epidemiology, treatment, and prognostic factors 
2 
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1.3 Pathophysiology 
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shown that macrophages (MΦs) play a central role in IFN-γ-related stem 
cell destruction. Specifically, they produce tumor necrosis factor-a 
(TNF-a), engage cytotoxic T cells, and consequently enhance the 
production of IFN-γ, forming an interactive loop44-46. Another important 
aspect involves regulatory T cells (Tregs), which are decreased in AA. 
There are some indications that the number of Tregs or a unique subtype 
of Tregs is correlated with the response to ATG treatment, and Tregs 
appear to increase with the response to treatment47-49. Interleukin (IL)-
17-producing CD4+ cells (Th17) play a pivotal role in autoimmunity50, 
and although AA does not share many similarities with autoimmune 
diseases, Th17 cells are increased (SAA) and seem to play a role during 
the early stage of AA51,52.  
 
1.3.2 Telomeres 
Even though immune destruction of hematopoietic cells is the leading 
cause of AA, up to 1/3 of patients have short telomeres, and in some 
cases, these are caused by mutations in the telomerase gene complex53,54. 
Telomeres are nucleotide repeats at the ends of chromosomes, which 
protect them from damage. Telomere maintenance requires the 
telomerase ribonucleoprotein complex, which consists of telomerase 
reverse transcriptase (TERT) and its RNA template (TERC)55,56. 
Originally, telomere shortening was thought to be the result of a higher 
than normal number of progenitor cell divisions to produce a mature 
cell53,57. Nevertheless, discoveries in congenital AAs, such as 
dyskeratosis congenita (DC), Fanconi anemia (FA), and Shwachman-
Diamond syndrome, helped to connect genetic lesions and telomere 
shortening of hematopoietic cells58,59. Mutations in TERT and TERC 
genes have been found in 4%–10% of AA patients53,60. AA patients with 
short telomeres appear to have dismal overall survival (OS) after IST 
and a significantly higher risk for relapse and clonal evolution54. 
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1.3.3 Clonality 
Although AA is a non-malignant disease, it has a well-accepted 
association with clonal hematopoiesis61,62. The most used phrase is 
clonal evolution, which can occur many years after the initial diagnosis 
and describes when AA transforms to a myelodysplastic syndrome 
(MDS) or acute myeloid leukemia (AML). In different studies, the long-
term risk for developing AML or MDS ranged between 5%–20%, and 
it often involves the loss of all or a portion of chromosome 763-68. 
However, it is not uncommon for AA patients to have chromosomal 
abnormalities at the time of diagnosis or acquire them during the course 
of the disease69,70 without further development of malignancy3,68. The 
responses to IST and survival appear to be similar between patients with 
and without cytogenetic aberrations71, but patients with monosomy 7 
respond poorly to IST70.  
 
Next-generation sequencing has identified several mutations in specific 
genes, adding evidence of the clonal nature of AA. Most of the 
mutations are known from myeloid malignancies, but AA differs from 
malignancies in its limited set of mutations and clone size72,73. Previous 
studies have shown that clonal populations are present in 19% to 47% 
of AA patients, and the common somatic mutations are DNMT3A, 
ASXL1, BCOR, BCORL1, and PIGA72,73. These mutations have also 
been associated with the clinical outcome and prognosis; patients with 
PIGA, BCOR, and BCORL1 respond well to IST and have better OS 
compared with patients with DNMT3A and ASXL1 mutations72. In 
another study, the presence of DNMT3A and ASXL1 increased the risk 
for MDS development73. 
 
Paroxysmal nocturnal hemoglobinuria (PNH) provides historical and 
considerable evidence of benign clonal hematopoiesis61. PNH is caused 
by mutations in the X-linked gene PIGA, which encodes 
phosphatidylinositol N-acetylglucosaminyltransferase subunit A 
(PIGA)  involved in the synthesis of glycosylphosphatidylinositol (GPI), 
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making the cell surface extremely sensitive to complement attack74,75. 
PNH is strongly associated with bone marrow failure. It is believed that 
the cell-mediated autoimmune attack that causes AA may spare 
selectively GPI-negative hematopoietic stem cells, providing a growth 
advantage for the PIGA- mutant GPI-negative clone74. More than 50% 
of AA patients have a PNH clone, most of which have a clone size of 
<10%, and the development to a symptomatic PNH disease occurs in 
2%–19% of AA cases76-80. Nevertheless, the progression to acute 
leukemia in patients with PNH and from PNH clones in patients with 
marrow failure is rare61,81. 
 
AA development has also been associated with specific human 
leukocyte antigens (HLA)82. Class I HLA molecules, such as HLA 
A02:01, A02:06, A31:01, and B4:02, can act as auto-antigens and are 
targeted by cytotoxic T cells83. A substantial proportion of AA patients 
have clonal hematopoiesis characterized by the loss of specific HLA 
alleles as a result of acquired copy number-neutral loss of heterozygosity 
(CNN-LOH) on the short arm of chromosome 6 (6pLOH)83. 6pLOH(+) 
clones have been detected in 11%–13% of AA patients. Reduced HLA 
auto-antigen expression gives stem cells an opportunity for clonal 
outgrowth as an “escape” from the autoimmune attack82-86. This may be 
the mechanism by which hematopoiesis is maintained for years in AA 
patients83.  
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1.4 Differential diagnosis 
AA is a diagnosis of exclusion, and there is no single test that reliably 
establishes an AA diagnosis (Figure 1). Other causes of pancytopenia 
(e.g., drugs or viruses), hypoplastic bone marrow, and inherited bone 
marrow failure syndromes (IBMFS) should be excluded. 
 
 
Figure 1. Differential diagnosis of aplastic anemia. Reproduced with 
permission from (Young, N; Aplastic anemia; N Engl J Med 2018;379;1643-
1656). Copyright Massachusetts Medical Society. 
 
 
1.4.1 Inherited bone marrow failure syndromes 
IBMFS are traditionally considered pediatric disorders, but they can also 
be diagnosed in adults. IBMFS are rare disorders, but the most common 
ones to develop to AA and evolve into MDS and AML are FA, DC, and 
GATA2 spectrum disorders87. Patients with IBMFS often have both 
physical and hematologic findings, but depending on the disease, they 
may not have any physical abnormalities.  
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Fanconi anemia 
FA is the most common inherited cause of bone marrow failure. Genes 
that are mutated in FA patients are termed FANC, and more than 20 have 
been identified; FANCA, FANCC, FANCG, and FANCD2 are the most 
common88,89. FA patients have a cumulative hematopoietic dysfunction 
likely related to an excess of genetic instability, cellular stress, p53 
activation, and cell death90.  Patients often present with congenital 
abnormalities, such as a short statue, microphthalmia, thumb and radius 
deformities, skin hyperpigmentation, and other signs, but approximately 
25% have no physical signs, and the disease can be missed during 
childhood. Up to 80% of FA patients have been reported to develop bone 
marrow failure, and it usually occurs during the first or second decades 
of life 90,91. MDS or AML is diagnosed later on in the disease course, 
and the risk to develop solid tumors increases with age92.  
 
Dyskeratosis congenita 
DC is a disease in which many patients reach adulthood before 
diagnosis. Possible physical signs increase with age, and more than half 
of the patients are diagnosed later than 15 years of age87. Dysplastic 
nails, oral leukoplakia, hypogonadism, lacrimal duct stenosis, early 
greying, and liver and pulmonary fibrosis can all be symptoms of DC. 
Since 1998, eleven DC genes have been identified89. Several of them are 
essential in telomere maintenance, which becomes defective and leads 
to very short telomeres. DC can have different inheritance patterns. 
DKC1 is responsible for X-linked DC and often found in children89. 
Autosomal dominant DC is heterogeneous, and three mutations, 
including TERC, TERT, and TINF2, have been recognized89. 
Autosomal-recessive DC has been associated with NOP10 and NHP2 
mutations93.  Bone marrow failure is a frequent complication in DC (in 
up to 80% of patients), and it often develops in the second or third 
decade but can develop from any time after birth to the seventh decade 
of life87,93. DC patients generally have a 4-fold higher risk for 
developing malignancies, but a substantially higher risk is noted for 
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some types of tumors, including head and neck carcinomas (~70-fold), 
MDS (~500-fold), and AML (~70-fold)94. 
 
GATA2 spectrum disorders 
GATA2 is a transcription factor essential for hematopoiesis by 
maintaining the pool of hematopoietic stem cells95. GATA2 deficiency 
has a broad clinical spectrum that includes viral and bacterial infections, 
lymphedema, deafness, alveolar proteinosis, monocytopenia, and low B, 
T, and NK cells, and it is associated with bone marrow failure, MDS, 
and AML96. GATA2 mutations associated with bone marrow failure 
result in loss of function and GATA2 haploinsufficiency89. Patients with 
GATA2 deficiency have a high risk of developing MDS and leukemia97, 
and MDS is typically hypocellular. Additionally, the most common 
cytogenetic aberration is monosomy 7, but other abnormalities, such as 
trisomy 8 and trisomy 21, have also been described95. Flow cytometry 
analysis of GATA2 patient bone marrow samples showed a concomitant 
reduction in monocytes, B cells, and NK cells, which were significantly 
lower than in AA patients98. 
 
 
1.4.2 Hypoplastic myelodysplastic syndrome 
The diagnosis of a MDS requires morphological dysplasia in 10% of 
one or more myeloid lineages99, and most patients have a hypercellular 
or normocellular marrow. Still, 10%–20% of MDS patients have 
cellularity under 30%, having a hypoplastic MDS (hMDS)100,101. 
Distinguishing hMDS from AA can be difficult; using only 
morphological alterations is challenging because of the low number of 
assessable cells. The detection of clonal markers as a chromosomal 
aberration or molecular marker can be helpful, but some overlapping 
with AA occurs102. However, dysplastic megakaryocytes, a normal or 
increased number of CD34 cells, and some mutations are not consistent 
with AA103-106. Spliceosome genes mutations and multiple mutated 
genes are characteristic for MDS but not AA72,107. Patients with hMDS 
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have a higher risk of developing leukemia and shorter OS compared 
with AA106,108.  
 
Differentiating between pediatric bone marrow failure syndromes is 
challenging. The most common form of pediatric MDS is refractory 
cytopenia characterized by a hypocellular bone marrow with a normal 
karyotype109,110. Somatic mutations and inherited constitutional 
mutations should be analyzed for correct diagnosis and treatment89,110. 
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1.5 Treatment 
Patients with SAA or VSAA have a direct indication of treatment. 
NSAA has a different clinical course of the disease as they can develop 
SAA or be stable for years. Spontaneous recoveries occur but are 
rare111,112. NSAA patients can be monitored with blood tests and treated 
when they become dependent on transfusions or have a neutrophil count 
<0.5×109/l113. Current treatment recommendations stratify patients 
according to age and the availability of an HLA-matched sibling donor 
(Figure 2)3,113,114. However, the choice between hematopoietic stem cell 
transplantation (HSCT) and IST is not always clear-cut, and both 
comorbidities and the severity of AA should be taken into account115.  
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Treatment of acquired aplastic anemia; Reprinted from, Brit. J. 
Haematol;172(2), Killick, B.S, et al; Guidelines for the diagnosis and 
management of adult aplastic anaemia, Pages No 187-207, Copyright (2016), 
with permission from Elsevier. 
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1.5.1 Hematopoietic stem cell transplantation  
The replacement of failing bone marrow with a healthy one is a curative 
treatment for AA patients. HSCT has several complications, and GvHD 
remains one of the most feared reactions. It is the major cause of non-
relapse mortality after HSCT. Patients with severe chronic (c)GvHD 
have decreased quality of life, and the long-term mortality rate increases 
to 50%116,117.  
 
The choice of primary treatment depends on the availability of an HLA-
matched sibling donor, and patients <40 (-50) years of age with a sibling 
donor should undergo transplantation as the first-line treatment113. 
These recommendations have been changed over the years. As early as 
1988, it was established that patients <20 years of age had better OS 
with an HLA-matched sibling donor HSCT than IST (66% vs. 56%); 
this was especially true for patients with VSAA (64% vs. 38%, p=0.01). 
Older patients with VSAA responded poorly to both treatments (OS 
44% HSCT vs. 43% IST), but SAA patients had better survival with IST 
(82%) than HSCT (62%)10. In 1995, HSCT was also suggested for 
patients 20–45 years of age27. However, even though studies still show 
exceptionally promising HSCT results for younger patients, patients >40 
years of age have a considerably inferior outcome. A European Group 
for Blood and Marrow Transplantation (EBMT) study from the year 
2000 showed better results for young (<20 years of age) patients with 
low neutrophil counts (<0.2×109/l) receiving HSCT118. A follow-up 
study from 2016 that compared the findings from before and after 1999 
confirmed the superior results for the younger group, in which the OS 
after HSCT was 86%, and patients 21–40 years of age also had a high 
OS with HSCT (76% compared with 65% for IST, p=0.6). Nevertheless, 
patients >40 years of age showed a worse OS with HSCT (IST 58% and 
HSCT 56%, p=0.006)119. Patients >40 years of age had a declining OS: 
40–49 years 67%, 50–59 years 58%, and >60 years 48% (p<0.0001)120. 
It is well-known that older patients have higher transplant-related 
mortality (TRM), and a low performance score pre-transplant has been 
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shown to increase the mortality risk121. As infections, GvHD, and 
toxicity are the main reasons for death, questions of the most appropriate 
conditioning regimen and the optimal GvHD prophylaxis have been 
raised120,122,123. 
  
Bone marrow (BM) has been widely used as a stem cell source for 
HSCT in AA patients. At the beginning of the 21st century, when 
peripheral blood stem cells (PBSCs) were being increasingly used, a 
switch from BM to PBSC occurred. This also led to studies comparing 
the transplant results using BM or PBSCs. A large study combining data 
from EBMT and the Center for International Blood and Marrow 
Transplant Research (CIBMTR) was published in 2007 and included 
692 AA patients. A clear advantage for BM was observed in the <20 
years of age group, with a better OS (85% vs. 73%), as well as a lower 
risk for cGvHD124. In another study, the survival of patients receiving 
BM was 84% compared with 68% for PBSCs  (p<0.0001), and this 
advantage was present in all age groups (<20 years: 90% vs. 76% and 
>20 years: 74% vs. 64%, respectively)125. As a result, BM is currently 
the preferred stem cell source for transplantation in AA113, even though 
some studies reported no differences in OS or GvHD using PBSCs 
instead of BM120. 
 
As only a few patients have an HLA-matched sibling donor, the first 
attempts to use unrelated donors (URDs) was made in the 1980s. The 
probability of long-term survival after an URD transplantation in AA 
ranged from 29% to 50%126-129. Since then, the results have improved 
with the introduction of high-resolution HLA typing and the use of 
fludarabine-based conditioning, low dose total body irradiation, and the 
CD52-antibody alemtuzumab130-133. An EBMT study on SAA patients 
transplanted between 1990 and 2005 found that cohorts transplanted 
before and after 1998 significantly differed in outcomes. The 5-year 
survival increased from 32% before 1998 to 57% for those transplanted 
after (p<0.0001), and the improved survival was associated with less 
graft failure and reduced acute and chronic GvHD134. Another EBMT 
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analysis of 1448 AA patients transplanted between 2005 and 2009 
included 508 URD transplants, which showed significantly more acute 
grade II–IV (25% vs 14%) and chronic GvHD (26% vs 14%). In survival 
analyses, URD compared with an HLA-matched sibling donor graft was 
not a statistically significant predictor135. The OS after an URD graft is 
currently >70% for adult patients (up to 40 years of age) and >90% for 
children (<18 years of age)136-139. Therefore, URD transplantation is 
recommended as a second-line treatment for adults but can be used as a 
first-line treatment for children137. 
 
In addition to well-defined transplantation options with an HLA-
matched sibling donor or an URD, alternative stem cell sources, such as 
cord blood or a haploidentical donor, have been used. These may also 
be curative, but the risk of graft rejection, infectious complications, and 
GvHD are higher140. A large cohort study of unrelated cord blood 
transplantation between 1996 and 2009 showed an estimated 3-year OS 
of 38%. The major cause of death was graft failure and infections141. 
More recently, an increasingly used option is haploidentical 
transplantation. Almost 400 AA patients have been transplanted, and 
encouraging results have been reported mainly in the pediatric 
population and young adults142. The median overall engraftment rate 
was 92%, and the median risk of grade 2–4 acute GvHD was 12%, with 
a median 1-year OS of 85%143. 
 
Apart from developing acute or chronic GvHD, HSCT is associated with 
other potential complications. Rejections are observed in 5%–15% of 
AA patients and can be reduced with the use of ATG, low-dose 
irradiation, fludarabine-based conditioning for URD grafts, and using a 
marrow cell dose higher than 2×108/kg114. Late complications include 
the development of solid tumors, the incidence of which has been 
reported to be 12%, and the most prominent locations were the skin, 
cervix, head and neck. The conditioning regimen, especially irradiation, 
and cGvHD were risk factors. Another late complication is 
Krista Vaht 
15 
osteonecrosis, with an incidence of 15%–20%, and the risk factors were 
age, previous IST, and treatment with steroids144-146. 
 
 
1.5.2 Immunosuppressive treatment 
Today, the standard IST is horse anti-thymocyte globulin (hATG) and 
cyclosporine A (CsA), with hematologic recovery in 50% to 70% of 
cases77,114,147-151. Adding CsA to hATG considerably improved the 
response rate at three months (65% in the hATG/CsA group vs. 39% in 
the hATG group) and six months (70% vs. 46%, respectively)147. 
However, later attempts to enhance hATG/CsA treatment by adding an 
additional immunosuppressive drug have been unsuccessful. 
Mycophenolate mofetil (MMF) inhibits the proliferation of activated 
lymphocytes and was anticipated to favor the induction of tolerance. The 
OR rate at six months was 62% with a 37% relapse rate, and more than 
half of the relapses occurred during MMF administration, suggesting 
that this drug was not effective in preventing relapses among 
responders152. Sirolimus blocks CsA-resistant pathways and inhibits T 
cell activation. A study in which sirolimus was added to hATG + CsA 
showed no differences in the OR rate at either three or six months (37% 
and 51% for the hATG/CsA/sirolimus group and 50% and 62% for the 
hATG/CsA group, respectively)153. Alternative treatment regimens, 
such as alemtuzumab and cyclophosphamide, have also been used for 
AA treatment. As first-line treatment, alemtuzumab achieved only a 
19% response rate154 and is not currently recommended. 
Cyclophosphamide administered at moderate or high (30–200 mg/kg) 
doses is reported to be too toxic, causing prolonged neutropenia and a 
high incidence of fungal infections and mortality155,156. 
 
IST is offered as a first-line treatment to patients without an HLA-
matched sibling donor or those >40 years of age113. There are several 
ATG products available with different efficacies. All ATG products 
have a lymphocyte-depleting effect, but rabbit ATG (rATG) causes 
more severe depletion of CD4+ T cells and Tregs157. However, this 
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biological effect does not translate into a better clinical outcome. Several 
studies comparing hATG with rATG have shown both an inferior 
hematological response (68%–79% for hATG vs. 37%–53% for 
rATG)157-160 and OS (96% for hATG vs. 76% for rATG)157. In contrast, 
some studies have found a similar response rate between different ATG 
formulations158,161. However, the only randomized study157 has shown 
the superiority of hATG, which is considered to be more effective and 
the preferred first-line treatment. 
 
The OS after ATG treatment is age-dependent. An  EBMT study of 192 
patients treated with hATG and CsA with or without granulocyte colony 
stimulating factor showed that the OS at 15 years was 89%±12% for 
patients >20 years, 81%±13% for patients 20–39 years, 55%±15% for 
patients 40–59 years, and 32%±16% for patients ≥60 years67. Similar 
results of decreased OS for patients >40 years have been reported in 
several studies115,159,162-164. Recently, a study involving 955 patients 
receiving Thymoglobulin® treatment showed similar 10-year survival 
numbers: patients <20 years 80%, 21–40 years 70%, 41–60 years 49%, 
and over 60 years 38%165. Instead, children treated with IST have an 
excellent outcome in most studies, and the survival comparison with 
HSCT does not differ considerably, but event-free/failure-free survival 
has been significantly inferior in patients receiving IST (33%–64%)166-
168. 
 
The response and survival after ATG treatment additionally depend on 
the AA severity grade. For NSAA, ATG + CsA compared with CsA 
alone resulted in significantly higher response rates (74% vs. 46%, 
respectively)169. VSAA patients have a similar response to treatment as 
SAA patients depending on the ATG type (30%–50%)160,170,171, except 
for children with VSAA who have been reported to achieve more 
complete responses (CRs) than SAA patients (68% vs. 45%)172. Patients 
with VSAA have higher infection rates (44%) during the first 90 days 
compared with SAA patients (22%)79, and higher mortality. The 5-year 
survival is lower for VSAA (76%) compared with SAA (98%) 
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patients173. As an exception, children with VSAA appear to have better 
survival compared with adults (83% vs. 62%)115.  
 
In addition to the AA severity grade, other predictive factors of patient 
response and survival have been identified based on hATG and CsA 
treatment. The response to ATG treatment is slow, and evaluation at six 
months after IST is recommended. In multivariate analysis, Scheinberg 
and coworkers found that younger age, higher baseline absolute 
reticulocyte counts (ARCs), and absolute lymphocyte counts (ALCs) 
were highly predictive of the response at six months. Patients with ARC 
≥25×109/l and ALC ≥1×109/l had a higher probability of response 
compared with patients with lower ARCs and ALCs (83% vs. 41%, 
respectively), which translated to a longer 5-year survival (92% vs. 
53%)170. 
 
Several complications are associated with IST, such as relapse, 
refractory disease, and clonal evolution. Up to 35% of patients 
experience relapse after IST78,174, and the second course of ATG results 
in a 55%–65% response rate, where responding patients have a good 
survival rate175,176. Refractory disease is more challenging to treat, and 
the response to the second course of ATG is around 30% (up to 70%)177-
179. In these cases, HSCT should be considered instead, especially for 
younger patients180,181. More than 40% of patients with refractory 
disease die from bleeding or infections within 5 years after their 
diagnosis182. Alemtuzumab monotherapy is equivalently effective as 
second-line ATG, with a hematologic response observed in 30%–40% 
of patients154. The risk of clonal evolution to MDS/AML is ~15%, and 
the development of hemolytic PNH occurs in 10%78. 
 
Eltrombopag was presented as a new treatment option in 2012. 
Eltrombopag is a thrombopoietin mimetic that binds to the receptor c-
MPL expressed on megakaryocytes, hematopoietic stem cells, and 
progenitor cells183. In the first study conducted by the National Institutes 
of Health (NIH), eltrombopag was used to treat refractory patients. 
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Twenty-five patients were treated, with a 44% hematologic response in 
at least one lineage183. In the second cohort, an additional 18 refractory 
patients were included, and the overall response rate was 40%. Five of 
the responding patients discontinued eltrombopag and continued to have 
normal marrow function. However, eight patients developed clonal 
cytogenetic abnormality during the treatment184. A new phase 2 study 
included 40 patients who had previously failed at least one ATG 
treatment. Targeted deep and whole-exome sequencing was performed. 
Fifty percent of the patients achieved a hematologic response, and 18% 
of the patients developed clonal evolution. Clonal evolution was an early 
event in 87% of the patients and occurred within six months of 
eltrombopag initiation, suggesting a direct link between eltrombopag 
treatment and clonal evolution, and thus close monitoring with bone 
marrow samples is warranted185. Eltrombopag has also been used for 
untreated patients in combination with hATG/CsA. Eltrombopag was 
given as a 150 mg daily dose and at different time points depending on 
the cohort. Promising results were observed, especially in the third 
cohort who received eltrombopag from days 1 to 180. The overall 
response rate at six months was 94%, and the survival rate at 2 years for 
all patients was 97%. Clonal evolution occurred early and in a total of 7 
(7.6%) patients186.  
 
 
1.6 Population-based studies 
Although randomized clinical studies are the most suitable to compare 
different treatments, a population-based study on a cohort representing 
a defined population (e.g., geographic boundaries) offers some 
advantages, especially in external validity. Randomized trials usually 
represent a selected cohort of patients; several patients are excluded 
because of age, co-morbidities, or patient refusal187. Other studies, such 
as registry and single-center studies, can be biased depending on the 
reporting activity and type of patients treated in a specific center. 
Transplant centers usually treat younger patients and report their results 
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to the transplant registries. Patients treated in smaller hospitals can be 
lost to follow-up, and their long-term outcomes not reported. Real 
population-based studies in AA are difficult to perform because of the 
lack of nationwide AA registries collecting information on treatments 
and outcomes.  
Most AA studies have been performed on selected patient cohorts, such 
as randomized trials, transplant registry studies, and single-center 
reports, in which most included patients were also young. Moreover, 
numerous epidemiological studies on AA from Europe, the United 
States, South America, and Asia from 1970 until the 1990s have 
reported outcome data with short follow-up periods11,14,17. The latest 
epidemiological study in Scandinavia was issued in 1996 and focused 
on pediatric population188. The importance of complete longitudinal 
population-based data was underlined at the International Working 
Group of Severe Aplastic Anemia meeting in 2010, where the 
foundation of a population-based registry for the longitudinal collection 
of data on AA patients from diagnosis to after treatment was 
proposed189. In Sweden, where disease codes of all patients are centrally 
registered, there exists an excellent opportunity to identify patients with 
AA and collect data on incidence, treatment, and outcomes of the entire 
population.  
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2 Aims  
The overall aim was to conduct a retrospective population-based study 
in patients with AA diagnosed in Sweden during the years 2000–2011, 
with emphasis on incidence, treatment, and survival. 
 
Paper I 
To determine the incidence of AA, type of treatment, and survival in 
the entire cohort. 
 
Paper II 
To analyze the AA patient cohort receiving ATG treatment, with a 
special focus on the following: (a) response rate and duration after first- 
and second-line ATG therapy, (b) response rate to different ATG 
formulations (horse and rabbit), (c) predictive clinical factors for patient 
response, and (d) survival. 
 
Paper III 
To analyze the allografted AA patient cohort, focusing on the effects of 
disease severity, stem cell source, and age and transplantation timing on 
patient survival, as well as causes of death and the new composite 
endpoint graft-versus-host disease-free, rejection-free survival (GRFS). 
 
Paper IV 
To determine the possible relationship between Tregs and MΦs and AA 
severity and responses to IST in the ATG-treated AA patient cohort by 
performing immunohistochemical staining in bone marrow biopsies 
from the time of diagnosis.  
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3 Patients and methods 
Identification of AA cases (paper I–IV) 
The Swedish National Patient Registry held by the Swedish National 
Board of Health and Welfare was used to identify new AA cases (both 
children and adults) diagnosed from 2000–2011 in Sweden. The registry 
includes data on all patients treated as in- or out-patients in the national 
health care system. The 10th version of the International Classification 
of Diseases (ICD) was used for the registry search, and the disease codes 
D61.0–D61.9 were applied. The initial evaluation showed more than 
5,700 cases. Because of the suspiciously high number of potential new 
cases, we performed a pilot study at the Sahlgrenska University Hospital 
in Gothenburg to evaluate the registry and establish new search criteria. 
Seven-hundred and twenty cases were found at the Sahlgrenska 
University Hospital, and all medical charts were evaluated. Fifty-seven 
valid AA cases were identified. The other patients did not fulfill the 
diagnostic criteria, had a false diagnosis code (clerical error), had 
secondary anemia because of other diseases (e.g., cancer or rheumatic 
diseases), or had congenital AA. A common finding was that all genuine 
cases of AA were diagnosed at the departments of internal medicine, 
hematology, infectious diseases, or pediatrics. Additionally, all AA 
patients had more than one medical contact with a D61.0–D61.9 
diagnosis code. When the cut-off level was set as at least two medical 
contacts and a diagnosis code of D61.0–D61.9, only one genuine AA 
case was missed. Based on the pilot study, the following new search 
criteria for the registry were established: 1) one of the codes from 
D61.0–D61.9, 2) at least two medical contacts with this diagnosis code, 
and 3) the diagnosis was made in the internal medicine, hematology, 
infectious diseases, or pediatrics department. A new national search 
revealed 1,362 unique patients with a potential diagnosis of AA, and all 
medical charts were thoroughly analyzed (Figure 3). Data were 
collected from the treating hospitals (university hospital, n=7; regional 
and county hospitals, n=29) in case report forms, and unclear cases were  
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Figure 3. Identification of cases from the Swedish National Patients Registry 
and allocation between papers I-IV. AL-acute leukemia; MDS-myelodysplastic 
syndrome; PNH-paroxysmal nocturnal hemoglobinuria; PRCA-pure red cell 
anemia 
 
re-evaluated. Follow-up information was acquired from medical charts 
and the Swedish Cause of Death Registry. 
The diagnosis of AA and AA severity grade was confirmed according 
to the Camitta criteria. Patients with congenital disease, pancytopenia 
without a marrow biopsy performed, marrow fibrosis, or other signs of 
malignancy or dysplasia were excluded. Mild dysplasia in 
erythropoiesis was accepted. The patient allocation between papers I–
IV is shown in Figure 3. 
 
Immunohistochemistry (paper IV) 
Paraffin-embedded bone marrow tissue blocks were used to produce 
whole tissue sections with a thickness of 4 microns. After routine 
deparaffinization, sections were stained with CD68 (Agilent, Ca, United 
States), CD163 and FOXP3 (BioCare, CA, United States), and IL-17 
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(Abcam, Cambridge, UK). The PT Link/PT200 HIER, Heat-Induced 
Epitope Retrieval, and Autostainer Link 48 were used. The choice of 
antibodies was based on the following: CD68 (for MΦs subtype M1) 
and CD163 (for subtype M2) are proteins expressed on monocyte-
macrophage lineage cells, IL-17 is a marker of Th17 cells,  and forkhead 
box protein 3 (FOXP3) is a well-recognized marker of Tregs. The 
counting of positively stained cells was performed digitally using 
NDP.view2 software from Hamamatsu, Japan. Cells with positive 
staining, nuclear (FOXP3) or cytoplasmatic (IL-17) for lymphocytes, 
and cytoplasmatic (CD68, CD163) in the large white cells with abundant 
cytoplasm with or without filopodia and detectable medium to large 
nuclei were counted in ten consecutive high-power fields (HPF). 
Microscope Zeiss Axioscope 2 Plus with the optical field of view (FOV) 
23 was used as a standard for digital HPFs, giving a calculated area of 
0.26 mm2 per HPF. 
 
Statistical methods 
Rates and proportions were compared using Pearson’s chi-squared test. 
The Kaplan–Meier method was used to estimate overall survival, and 
comparisons were based on the log-rank test. Uni- and multi-variable 
Cox regression proportional hazards were used to analyze factors 
influencing survival and a logistic regression analysis for predictive 
factors for response to treatment. The statistical analyses were 
performed either by SPSS versions 23–26 or Stata for Macintosh version 
13.1, and the relative survival ratio was calculated using the strs module. 
 
Ethical aspects 
The studies were approved by the Regional Ethical Review Board in 
Gothenburg (615-12). For healthy individuals included in paper IV, the 
Swedish Ethical Review Authority approved the study (2019-04900), 
and they all provided informed written consent. 
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4 Results 
Paper I 
Of 1,362 potential cases, we identified 257 new AA cases diagnosed 
between 2000 and 2011 (Figure 3). The overall incidence was 2.35 
cases per million inhabitants per year. Biphasic age distribution was 
observed with one peak in patients aged 15–20 years (2.89) and one in 
patients >60 years old (4.36). The median age at diagnosis was 60 years, 
and 52% of the patients were female. At diagnosis, 38% had NSAA, 
38% had SAA, and 24% had VSAA. First-line treatments included IST 
(63%), 10% underwent HSCT, and 27% were treated with single-agent 
CsA or no specific therapy. The median follow-up was 76 months, and 
47% died during follow-up. Almost 2/3 of the patients (n=74) died 
within 24 months, most frequently due to infections (n=41) or bleeding 
(n=14).  
 
The 5-year survival for all patients with AA was 60.7%, and it was 
influenced by age as follows: 90.7% in 0–18 years, 90.5% in 19–39 
years, 70.7% in 40–59 years, and 38.1% in the ≥60 years age group 
(Figure 4A). Grouping patients according to disease severity showed a 
lower 5-year survival in patients with VSAA compared with SAA but 
not NSAA. According to treatment modality, the 5-year survival was 
96% in HSCT patients, 68.9% in the IST group, and 29.6% in patients 
who received CsA alone/no specific therapy (Figure 4B).  
 
The Cox regression analysis revealed that age (40–59 and ≥60 groups), 
VSAA, and treatment with CsA alone/no therapy were independent risk 
factors for inferior survival. The relative 5-year survival for all patients 
was 65.4%, and according to the median age at diagnosis, the relative 5-
year survival was 84.6% in patients less than 60 years but significantly 
worse for patients ≥60 years (45.3%). 
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Figure 4. A. Overall survival by age group; B. Overall survival according to 
primary treatment. SCT- hematopoietic stem cell transplantation (HSCT). 
Reproduced with permission from (Vaht K, et al; Incidence and outcome of 
acquired aplastic anemia: real-world data from patients diagnosed in Sweden 
from 2000-2011. Haematologica. 2017;102(10):1683-1690), Copyright 
Ferrata Storti Foundation.   
 
 
Paper II 
A total of 158 patients treated with first-line ATG were included in this 
study. The median age was 53 years, and most of the patients (64%) had 
SAA or VSAA at diagnosis, which increased to 84% at the time of 
treatment initiation. Different ATG formulations were used, including 
rATG in 128 patients and hATG in 27 patients. 
  
The best cumulative overall response (OR) was 47%, 25% reached CR, 
and 22% achieved partial response (PR). The OR rate was similar among 
the different age groups. The AA severity grade, especially at the time 
of the start of treatment, influenced the response rate (VSAA 22.7%, 
SAA 54.5%, and NSAA 88.5%). No significant difference in the 
response rate was observed between hATG (51.9%) and rATG (45.3%). 
 
B A 
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The 5-year OS for all patients was 69.6%, and it was age-related. 
Patients in the age group of 0–18 years had an OS of 86.2%; 19–39, 
90%; 40–59, 71.9%; 60–69, 56.1%; and ≥70, 46.2%. Disease severity at 
the time of ATG treatment initiation affected survival. Specifically, the 
OS rates for the VSAA, SAA, and NSAA groups were 53%, 77.3%, and 
92.3%, respectively (Figure 5A). Patients responding with CR and PR 
had a comparable 5-year OS of 89.7%, and 88.6%, respectively, but non-
responding patients showed an inferior outcome with an OS of 52.4% 
(Figure 5B).  
 
   
  
  
Figure 5. A. Overall survival by disease severity at the initiation of the 
treatment; B. Overall survival by response to the treatment. Reproduced with 
permission from (Vaht K, et al; Low response rate to ATG-based 
immunosuppressive therapy in very severe aplastic anaemia - A Swedish 
nationwide cohort study. Eur J Haematol. 2018;100(6):613-620), Copyright 
John Wiley and Sons. License 4822541059368. 
 
 
Considering the predictive factors, univariable logistic regression 
analysis showed that the well-known risk factor ARC <25×109/l at 
diagnosis was highly predictive for a poor response; the same was true 
for both SAA and VSAA at the time of treatment initiation. In a 
multivariable analysis, only SAA and VSAA were independent factors 
B A 
Krista Vaht 
27 
for an inferior response. A logistic model for response prediction 
containing ARC <25×109/l or ≥25×109/l at diagnosis and disease 
severity at the time of treatment initiation revealed that the response 
probability for patients with VSAA and ARC <25×109/l was only 19%, 
whereas patients with NSAA and ARC ≥25×109/l had a response 
probability of 90%. 
 
 
Paper III 
Sixty-eight patients who underwent HSCT were included. The median 
age at transplantation was 22 years, seventeen patients were ³40 years 
of age, and 27 patients were children £18 years old. Sixty-three percent 
of patients had been previously treated with one or more courses of IST.  
In more than 50% of cases, the donors were unrelated, and the most 
common stem cell graft was BM (n=54). According to the type of donor, 
different conditioning regimes were exploited and included 
combinations between cyclophosphamide, fludarabine, ATG, and 
irradiation. Immunosuppression was given with calcineurin inhibitors 
(in most cases CsA) in combination with methotrexate or other drugs. 
The median treatment duration with calcineurin inhibitors for patients 
surviving ³4 weeks was 436 days. Graft failure was observed in eight 
patients.  
 
Twenty-five patients developed acute GvHD, with 16% showing grades 
III–IV. Eleven patients developed cGvHD, and six patients had 
moderate or severe cGvHD.  
 
The 5-year OS for all patients was 86.8% (Figure 6A). TRM of the 
entire cohort was 13.2%, which was significantly higher for ³40-year-
old patients (29.4%) than in younger patients (7.8%). Patients aged <40 
years had a better 5-year OS of 92.2% compared with patients aged ³40 
years (70.6%) (Figure 6B).  
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Figure 6. A. Overall survival all patients; B. Overall survival according to 
age groups. Reprinted from, Biol Blood Marrow Transplant; 25(10); Vaht K 
et al; High Graft-versus-Host Disease-Free, Relapse/Rejection-Free Survival 
and Similar Outcome of Related and Unrelated Allogeneic Stem Cell 
Transplantation for Aplastic Anemia: A Nationwide Swedish Cohort Study; 
pages no1970-1974, Copyright (2019), with permission from Elsevier. 
 
 
We found no survival difference between HLA-matched sibling donor 
and URD recipients regarding all patients. Comparing children with 
adults, we divided patients into £18 and ³19 years of age and found a 
trend for better survival in children with 5-year OS rates of 96.3% and 
80.5%, respectively. However, no difference was observed when 
comparing young adults (19–39 years of age) with children. Further, 
when analyzing OS according to the stem cell source, we found no 
difference between BM (85.2%) and PBSCs (100%). 
 
In the entire patient cohort, GRFS at 1 and 5 years was 73.5% and 
69.1%, respectively. When dividing patients into age groups of <40 and 
³40 years, GRFS at 1 and 5 years was 80.4% vs. 52.9% and 74.5% vs. 
52.9%, respectively.  
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Paper IV 
Patients treated with ATG therapy and available bio-banked bone 
marrow biopsy samples at the time of diagnosis (n=121) and healthy 
age- and sex-matched volunteers as the control group (n=14) were 
included in this study. We found that the median number of positive 
cells per HPF was 0 for FOXP3, 0 for IL-17, 13 for CD68, and 24 for 
CD163. FOXP3, IL-17, CD68, and CD163 values were all lower in AA 
patients compared with healthy controls (Figure 7A-L).  
 
 
Figure 7. Immunohistochemical staining of CD68, CD163,  FOXP3, and IL-
17 protein in BM samples of aplastic anemia patients (magnification: ~40x)  
A. CD68 low; B.CD68 high; C. CD68 healthy control; D.CD163 low; 
E.CD163 high; F. CD163 healthy control; G. FOXP3 low; H. FOXP3 high; I. 
FOXP3 healthy control; J. IL-17 low; K. IL-17 high; L. IL-17 healthy control. 
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pages no1970-1974, Copyright (2019), with permission from Elsevier. 
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Paper IV 
Patients treated with ATG therapy and available bio-banked bone 
marrow biopsy samples at the time of diagnosis (n=121) and healthy 
age- and sex-matched volunteers as the control group (n=14) were 
included in this study. We found that the median number of positive 
cells per HPF was 0 for FOXP3, 0 for IL-17, 13 for CD68, and 24 for 
CD163. FOXP3, IL-17, CD68, and CD163 values were all lower in AA 
patients compared with healthy controls (Figure 7A-L).  
 
 
Figure 7. Immunohistochemical staining of CD68, CD163,  FOXP3, and IL-
17 protein in BM samples of aplastic anemia patients (magnification: ~40x)  
A. CD68 low; B.CD68 high; C. CD68 healthy control; D.CD163 low; 
E.CD163 high; F. CD163 healthy control; G. FOXP3 low; H. FOXP3 high; I. 
FOXP3 healthy control; J. IL-17 low; K. IL-17 high; L. IL-17 healthy control. 
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We found no differences in FOXP3, IL-17, CD68, or CD163 numbers 
between AA subgroups. Regarding the response, 48.8% of patients 
responded to first-line ATG treatment. We found no significant 
differences in the response when dividing patients into two groups 
according to the median values of FOXP3, IL-17, CD68, and CD163 
positive cells. When analyzing the response according to ARC and 
ALC, we found that patients with ARC ≥25 had a better response (65.9% 
vs. 32.7%) than the <25 group. For ALC, we found no differences in 
response. 
 
The 5-year OS for all patients was 67.8%. When the cohort was divided 
according to the FOXP3, IL-17, and CD68 median values, no 
differences were found in OS. However, when analyzing survival 
according to the CD163 median subgroups, we found a survival benefit 
for patients with above-median numbers of CD163-positive cells with 
an OS of 79.6% vs. 57.4% (Figure 8). When dividing patients according 
to AA severity, we only found a significant difference between CD163 
median subgroups in NSAA patients (5-year OS 89.5% vs. 57.9%). 
 
 
 
Figure 8. The 5-year survival according to median value of CD163. 
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5 Discussion 
In this population-based study on AA patients diagnosed from 2000–
2011 in Sweden, we found that the incidence was 2.35 per million 
inhabitants per year with a biphasic distribution. Although early studies 
showed broad variation in incidence, the IAAS study established a well-
accepted overall incidence of ~2 cases per million people9. A follow-up 
study by the Spanish group confirmed these results, showing an 
incidence of 2.34 cases per million per year16. Our incidence data 
correspond with the previously mentioned studies and show that the AA 
incidence has not changed since the 1980s.  
 
The 5-year survival in younger patients up to 40 years of age was around 
90%, and we found no difference in survival when comparing IST and 
HSCT as the primary treatment. Our survival data are consistent with 
other clinical trials reporting ATG and HSCT registry data119,130,157,158. 
Patients ≥60 years had a 5-year survival <40% and relative 5-year 
survival of 45%, showing a significant increase in mortality. These older 
patients had a higher risk of early death than younger ones; 16% were 
deceased three months after diagnosis. We also observed that patients  
≥60 years treated with IST had a 5-year survival of ~50%, which is 
similar to the results reported from EBMT AA registry data164, implying 
that a higher percentage of older patients should be treated with IST. 
  
When analyzing patients treated with first-line ATG, we found that the 
OR rate was 47%, and there were no age-related differences in response 
rates. Several studies have shown that younger patients respond better 
to ATG 153,164, but different ATG formulations were used compared with 
our data, and their patient cohorts were younger. Previous studies 
reported diverse response rates between 35% and 80%, depending on 
the ATG formulation157-159,190. Only one prospective randomized study 
has compared rATG and hATG treatments and found a better response 
rate (68% vs. 37%) and 3-year survival (96% vs. 76%) in the hATG 
group157. In our study, hATG and rATG treatment resulted in an equal 
Aplastic anemia - a population-based study of epidemiology, treatment, and prognostic factors 
30 
We found no differences in FOXP3, IL-17, CD68, or CD163 numbers 
between AA subgroups. Regarding the response, 48.8% of patients 
responded to first-line ATG treatment. We found no significant 
differences in the response when dividing patients into two groups 
according to the median values of FOXP3, IL-17, CD68, and CD163 
positive cells. When analyzing the response according to ARC and 
ALC, we found that patients with ARC ≥25 had a better response (65.9% 
vs. 32.7%) than the <25 group. For ALC, we found no differences in 
response. 
 
The 5-year OS for all patients was 67.8%. When the cohort was divided 
according to the FOXP3, IL-17, and CD68 median values, no 
differences were found in OS. However, when analyzing survival 
according to the CD163 median subgroups, we found a survival benefit 
for patients with above-median numbers of CD163-positive cells with 
an OS of 79.6% vs. 57.4% (Figure 8). When dividing patients according 
to AA severity, we only found a significant difference between CD163 
median subgroups in NSAA patients (5-year OS 89.5% vs. 57.9%). 
 
 
 
Figure 8. The 5-year survival according to median value of CD163. 
 
Months
60483624120
C
um
S
ur
vi
va
l
1 .0
0.8
0.6
0.4
0.2
0.0
CD163≥24
CD163<24
p=0.017
Krista Vaht 
31 
5 Discussion 
In this population-based study on AA patients diagnosed from 2000–
2011 in Sweden, we found that the incidence was 2.35 per million 
inhabitants per year with a biphasic distribution. Although early studies 
showed broad variation in incidence, the IAAS study established a well-
accepted overall incidence of ~2 cases per million people9. A follow-up 
study by the Spanish group confirmed these results, showing an 
incidence of 2.34 cases per million per year16. Our incidence data 
correspond with the previously mentioned studies and show that the AA 
incidence has not changed since the 1980s.  
 
The 5-year survival in younger patients up to 40 years of age was around 
90%, and we found no difference in survival when comparing IST and 
HSCT as the primary treatment. Our survival data are consistent with 
other clinical trials reporting ATG and HSCT registry data119,130,157,158. 
Patients ≥60 years had a 5-year survival <40% and relative 5-year 
survival of 45%, showing a significant increase in mortality. These older 
patients had a higher risk of early death than younger ones; 16% were 
deceased three months after diagnosis. We also observed that patients  
≥60 years treated with IST had a 5-year survival of ~50%, which is 
similar to the results reported from EBMT AA registry data164, implying 
that a higher percentage of older patients should be treated with IST. 
  
When analyzing patients treated with first-line ATG, we found that the 
OR rate was 47%, and there were no age-related differences in response 
rates. Several studies have shown that younger patients respond better 
to ATG 153,164, but different ATG formulations were used compared with 
our data, and their patient cohorts were younger. Previous studies 
reported diverse response rates between 35% and 80%, depending on 
the ATG formulation157-159,190. Only one prospective randomized study 
has compared rATG and hATG treatments and found a better response 
rate (68% vs. 37%) and 3-year survival (96% vs. 76%) in the hATG 
group157. In our study, hATG and rATG treatment resulted in an equal 
Aplastic anemia - a population-based study of epidemiology, treatment, and prognostic factors 
32 
response rate, which may have been influenced by the disparity in 
patient numbers between the groups (27 vs. 128, respectively). 
  
The disease severity at the time of treatment initiation significantly 
influenced the response to ATG. Only 22.7% of VSAA patients 
responded to treatment, and VSAA patients had only a 19% probability 
of responding according to a logistic regression prediction model that 
combined the pre-treatment stage and low ARC. In earlier studies, the 
response rates among VSAA patients were found to vary between 30% 
and 81%66,78,160,170, and hATG achieved a higher (50%–80%)78 response 
rate than rATG (30%–57%)160. Most of our patients received rATG 
(84.4%), and thus our data should be interpreted with caution. However, 
VSAA patients had a very good 5-year survival after HSCT of almost 
90% and 75% for patients >40 years, suggesting that selected VSAA 
patients, regardless of age, should be counseled for a HSCT as a first-
line therapy. 
  
Absolute reticulocyte count and ALC, together with disease severity, are 
important predictive factors for the response to ATG170. Nevertheless, 
alterations in the immune system have also been reported to be related 
to the response 48,52. We found that AA patients had a decreased number 
of Tregs (FOXP3-positive cells) compared with healthy controls, but no 
difference in the number of Tregs between AA severity groups or 
correlation between Tregs and the response or survival was observed. 
Tregs have reported to be decreased in AA, both in the peripheral blood 
and bone marrow, compared with healthy controls52,191,192. Moreover, 
the likelihood to respond to treatment appeared to be higher for patients 
with an increased number of Tregs at diagnosis49,52. However, our data 
indicate that the number of Tregs in the bone marrow of AA patients is 
not predictive for the response to ATG therapy. Regarding MΦs, and in 
contrast to the study by Sun et al44, we found that AA patients had fewer 
MΦs, both of the CD68 and CD163 subtypes, than healthy controls. In 
an AA mouse model, MΦs produced TNF-α and through the TNF-α 
receptor engaged effector T cells and increased the production of IFN-
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γ44. Additionally, in another mouse AA model, IFN-γ-dependent HSC 
loss required MΦs. IFN-γ was necessary for the selective maintenance 
of bone marrow MΦs, and depleting MΦs rescued stem cells but did not 
reduce T cell activation or IFN-γ production193. In our study, patients 
with a higher number of CD163-positive MΦs (for the M2 subtype) had 
better survival, and this potential benefit appeared to be limited to the 
NSAA group. MΦs polarization between M1 and M2 subtypes is 
unclear in AA immunology, but enhanced M2 MΦ activity was reported 
to be correlated with hematopoietic stem cell protection in an SAA 
mouse model193. We cannot explain the potential survival benefit of 
higher CD163/M2 MΦs mainly observed in the NSAA group by clinical 
characteristics, as we did not find any differences in the response to 
ATG, age, or transplantation rate between the high and low CD163 
patient groups. 
 
Transplanted patients had a very good 5-year survival of 87% and GRFS 
of 69.1%. Reasons for this promising outcome may include the use of 
ATG in conditioning together with long-term immunosuppression after 
transplantation. The positive effect of ATG on survival was 
demonstrated in the EBMT Severe Aplastic Anemia Working Party 
(SAAWP) study published 2015135 and the Latin American population-
based study, showing a superior event-free survival in the ATG group 
(79% vs. 61%)194. Age greatly influences survival after HSCT120. In the 
EBMT SAAWP study from 2015, negative predictors of survival apart 
from no ATG in the conditioning regimen included the use of PBSCs, a 
time lag from diagnosis to transplantation of >180 days, and patient age 
of >20 years. In our study, patients aged 0–19 and 20–39 years had 
similar outcomes, whereas patients aged over 40 had worse survival, 
mostly due to a higher TRM. Survival of older patients could be 
influenced by a more extended time from diagnosis to transplantation 
than younger patients; indeed, 4/5 patients >40 years transplanted as 
first-line treatment were long term survivors. Nevertheless, the outcome 
for older group appears to be unchanged during recent years120.  
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6 Conclusion 
Our population-based study included all identifiable patients with AA 
diagnosed in Sweden between 2000 and 2011 and should reflect the true 
incidence and survival. We can conclude that age is still a significant 
risk factor for inferior survival. We found that younger patients, 
regardless of the initial therapy, experienced a very good long-term 
survival. However, for patients ≥60 years, increased mortality was still 
considerable. In the transplant setting, age ≥40 years was already 
associated with unsatisfactory outcomes. Further, we found that only up 
to 50% of patients responded to ATG treatment, and in particular, the 
VSAA subgroup had a low possibility of response. Surprisingly, in ATG 
treated patients, the number of Tregs did not predict the response to 
treatment, and the number of M2 MΦs appeared to have a positive 
impact on survival, especially in NSAA patients, suggesting that M2 
MΦs could have possible prognostic importance in AA patients. 
In conclusion, the management of older patients with AA should be 
improved, and combination therapy of ATG with eltrombopag or earlier 
HSCT for selected patients (especially those with VSAA) may hopefully 
improve the outcome. 
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7 Future perspectives 
Survival after AA diagnosis is now considerably better than 50 years 
ago. However, older patients and patients with VSAA require a change 
in their treatment approach. Thrombopoietin (TPO) mimetics, which 
stimulate the stem cell pool via the c-MPL receptor, are the only 
available targeted therapy for AA. Eltrombopag has been used as a 
complementary treatment to IST, and promising results have been 
reported186. Further studies including treatment naïve AA patients are 
ongoing (NCT01623167, NCT02404025, and NCT04304820). In these 
studies, combination therapy with different ATG formulations or oral 
therapy with CsA is being investigated. The TPO-mimetic romiplostim 
is also being evaluated (NCT03957694, NCT04095936, and 
NCT02773290) in patients who are refractory and not suitable for IST 
or as a combination treatment with ATG and CsA. Hopefully, an oral 
combination of eltrombopag and CsA will be shown to be effective and 
can be used for older patients in the future. 
Another aspect is the direction towards earlier stem cell transplantation. 
However, as in our patient material, the lack of HLA-matched sibling or 
unrelated donors, which is the most common cause for repeated IST 
courses, is one obstacle. Haploidentical transplantation with 
posttransplant cyclophosphamide has shown promising results with a 
low incidence of acute and chronic GvHD195. In AA, patients who have 
undergone haploidentical HSCT were mostly children and young adults, 
with a 1-year survival of 80%–90%142. Furthermore, questions on the 
optimal conditioning and GvHD prophylaxis in older patients remain, 
and more data should become available before haplotransplantation can 
be considered as a standard treatment. Nevertheless, haploidentical 
transplantation appears to be an option for some refractory younger 
patients, and hopefully, data on older patients will soon be available. 
 
 
 
 
 
Aplastic anemia - a population-based study of epidemiology, treatment, and prognostic factors 
34 
6 Conclusion 
Our population-based study included all identifiable patients with AA 
diagnosed in Sweden between 2000 and 2011 and should reflect the true 
incidence and survival. We can conclude that age is still a significant 
risk factor for inferior survival. We found that younger patients, 
regardless of the initial therapy, experienced a very good long-term 
survival. However, for patients ≥60 years, increased mortality was still 
considerable. In the transplant setting, age ≥40 years was already 
associated with unsatisfactory outcomes. Further, we found that only up 
to 50% of patients responded to ATG treatment, and in particular, the 
VSAA subgroup had a low possibility of response. Surprisingly, in ATG 
treated patients, the number of Tregs did not predict the response to 
treatment, and the number of M2 MΦs appeared to have a positive 
impact on survival, especially in NSAA patients, suggesting that M2 
MΦs could have possible prognostic importance in AA patients. 
In conclusion, the management of older patients with AA should be 
improved, and combination therapy of ATG with eltrombopag or earlier 
HSCT for selected patients (especially those with VSAA) may hopefully 
improve the outcome. 
 
Krista Vaht 
35 
7 Future perspectives 
Survival after AA diagnosis is now considerably better than 50 years 
ago. However, older patients and patients with VSAA require a change 
in their treatment approach. Thrombopoietin (TPO) mimetics, which 
stimulate the stem cell pool via the c-MPL receptor, are the only 
available targeted therapy for AA. Eltrombopag has been used as a 
complementary treatment to IST, and promising results have been 
reported186. Further studies including treatment naïve AA patients are 
ongoing (NCT01623167, NCT02404025, and NCT04304820). In these 
studies, combination therapy with different ATG formulations or oral 
therapy with CsA is being investigated. The TPO-mimetic romiplostim 
is also being evaluated (NCT03957694, NCT04095936, and 
NCT02773290) in patients who are refractory and not suitable for IST 
or as a combination treatment with ATG and CsA. Hopefully, an oral 
combination of eltrombopag and CsA will be shown to be effective and 
can be used for older patients in the future. 
Another aspect is the direction towards earlier stem cell transplantation. 
However, as in our patient material, the lack of HLA-matched sibling or 
unrelated donors, which is the most common cause for repeated IST 
courses, is one obstacle. Haploidentical transplantation with 
posttransplant cyclophosphamide has shown promising results with a 
low incidence of acute and chronic GvHD195. In AA, patients who have 
undergone haploidentical HSCT were mostly children and young adults, 
with a 1-year survival of 80%–90%142. Furthermore, questions on the 
optimal conditioning and GvHD prophylaxis in older patients remain, 
and more data should become available before haplotransplantation can 
be considered as a standard treatment. Nevertheless, haploidentical 
transplantation appears to be an option for some refractory younger 
patients, and hopefully, data on older patients will soon be available. 
 
 
 
 
 
Aplastic anemia - a population-based study of epidemiology, treatment, and prognostic factors 
36 
Acknowledgement 
I want to thank all people who have contributed to the completion of this 
thesis. 
 
In particular, 
 
P-O Andersson, my principal supervisor for excellent guidance, 
commitment, encouragement, and not at least - patience. Thank you for being 
such a great friend! 
 
Mats Brune, my co-supervisor for introducing me to the field of 
transplantation and sharing your expertise and incredible enthusiasm.  
 
Per Ljungman for sharing your valuable knowledge in aplastic anemia and 
transplantation, and your involvement in designing the studies and writing 
the papers. 
 
All the co-authors for helping to gather the data, and as well for input in 
papers. 
 
My co-workers at Sahlgrenska University Hospital and Södra Älvsborg 
Hospital Borås, particularly YOU who decided to participate in our 
experimental study. 
 
Erik Holmberg for assistance with statistical analyses. 
 
Lõpetuseks, SUUR AITÄH emale ja Silvele kaasaelamise ja innustamise 
eest, ilma teieta oleks see kõik palju raskem olnud. 
 
 
 
 
 
 
 
 
 
 
37 
References 
1. Ehrlich P. Über einen Fall von Anämie mit Bemerkungen über 
regenerative Veränderungen des Knochenmarks. Charité-Annalen. 
1888;13:300-309. 
2. Vaquez N, Aubertin C. L'anemic pernicicuse d'apres les conceptions 
actuelles. Bull Mém Soc Méd Hop Paris. 1904;21:288-297. 
3. Young NS. Aplastic Anemia. N Engl J Med. 2018;379(17):1643-1656. 
4. Sharpe W. Benzene, artificial leather and aplastic anemia- Newark, 1916-
1928. Bull N Y Acad Med. 1993;69:47-90. 
5. Young NS, Kaufman DW. The epidemiology of acquired aplastic anemia. 
Haematologica. 2008;93(4):489-492. 
6. Lewis C, Putnam L, Hendricks F, Kerlan I, Welch H. Chloramphenicol 
(chloromycetin) in relation to blood dyscrasias with observations on other 
drugs. Antibiot Chemoter (Northfield). 1952;2(12):601-609. 
7. Young NS. Aquired Aplasic Anemia. JAMA. 1999;281:271-278. 
8. Camitta BM, Rappeport JM, Parkman R, Nathan DG. Selection of 
patients for bone marrow transplantation in severe aplastic anemia. Blood. 
1975;45(3):355-363. 
9. IAAS. Incidence of aplastic anemia: the relevance of diagnostic criteria. 
By the International Agranulocytosis and Aplastic Anemia Study. Blood. 
1987;70(6):1718-1721. 
10. Bacigalupo A, Hows J, Gluckman E, et al. Bone marrow transplantation 
(BMT) versus immunosuppressionfor the treatment of severe aplastic 
anaemia (SAA)- a report of the EBMT" SAA Working Party. British 
Journal of Haematology. 1988;70:177-182. 
11. Szklo M, Sensenbrenner L, Markowitz J, Weida S, Warm S, Linet M. 
Incidence of aplastic anemia in metropolitan Baltimore: a population-
based study. Blood. 1985;66(1):115-119. 
12. Böttiger L, Westholm B. Aplastic anaemia. I. Incidence and aetiology. 
Acta Med Scand. 1972;192(4):315-318. 
13. Davies S, Walker D. Aplastic anaemia in the Northern Region 1971-1978 
and follow-up of long term survivors. Clin lab Haemat. 1986;8:307-313. 
14. Cartwright RA, McKinney PA, Williams L, et al. Aplastic anaemia 
incidence in parts of the United Kingdom in 1985. Leuk Res. 
1988;12(6):459-463. 
15. Mary JY, Baumelou E, Guiguet M. Epidemiology of aplastic anemia in 
France: a prospective multicentric study. The French Cooperative Group 
for Epidemiological Study of Aplastic Anemia. Blood. 1990;75(8):1646-
1653. 
16. Montane E, Ibanez L, Vidal X, et al. Epidemiology of aplastic anemia: a 
prospective multicenter study. Haematologica. 2008;93(4):518-523. 
Aplastic anemia - a population-based study of epidemiology, treatment, and prognostic factors 
36 
Acknowledgement 
I want to thank all people who have contributed to the completion of this 
thesis. 
 
In particular, 
 
P-O Andersson, my principal supervisor for excellent guidance, 
commitment, encouragement, and not at least - patience. Thank you for being 
such a great friend! 
 
Mats Brune, my co-supervisor for introducing me to the field of 
transplantation and sharing your expertise and incredible enthusiasm.  
 
Per Ljungman for sharing your valuable knowledge in aplastic anemia and 
transplantation, and your involvement in designing the studies and writing 
the papers. 
 
All the co-authors for helping to gather the data, and as well for input in 
papers. 
 
My co-workers at Sahlgrenska University Hospital and Södra Älvsborg 
Hospital Borås, particularly YOU who decided to participate in our 
experimental study. 
 
Erik Holmberg for assistance with statistical analyses. 
 
Lõpetuseks, SUUR AITÄH emale ja Silvele kaasaelamise ja innustamise 
eest, ilma teieta oleks see kõik palju raskem olnud. 
 
 
 
 
 
 
 
 
 
 
37 
References 
1. Ehrlich P. Über einen Fall von Anämie mit Bemerkungen über 
regenerative Veränderungen des Knochenmarks. Charité-Annalen. 
1888;13:300-309. 
2. Vaquez N, Aubertin C. L'anemic pernicicuse d'apres les conceptions 
actuelles. Bull Mém Soc Méd Hop Paris. 1904;21:288-297. 
3. Young NS. Aplastic Anemia. N Engl J Med. 2018;379(17):1643-1656. 
4. Sharpe W. Benzene, artificial leather and aplastic anemia- Newark, 1916-
1928. Bull N Y Acad Med. 1993;69:47-90. 
5. Young NS, Kaufman DW. The epidemiology of acquired aplastic anemia. 
Haematologica. 2008;93(4):489-492. 
6. Lewis C, Putnam L, Hendricks F, Kerlan I, Welch H. Chloramphenicol 
(chloromycetin) in relation to blood dyscrasias with observations on other 
drugs. Antibiot Chemoter (Northfield). 1952;2(12):601-609. 
7. Young NS. Aquired Aplasic Anemia. JAMA. 1999;281:271-278. 
8. Camitta BM, Rappeport JM, Parkman R, Nathan DG. Selection of 
patients for bone marrow transplantation in severe aplastic anemia. Blood. 
1975;45(3):355-363. 
9. IAAS. Incidence of aplastic anemia: the relevance of diagnostic criteria. 
By the International Agranulocytosis and Aplastic Anemia Study. Blood. 
1987;70(6):1718-1721. 
10. Bacigalupo A, Hows J, Gluckman E, et al. Bone marrow transplantation 
(BMT) versus immunosuppressionfor the treatment of severe aplastic 
anaemia (SAA)- a report of the EBMT" SAA Working Party. British 
Journal of Haematology. 1988;70:177-182. 
11. Szklo M, Sensenbrenner L, Markowitz J, Weida S, Warm S, Linet M. 
Incidence of aplastic anemia in metropolitan Baltimore: a population-
based study. Blood. 1985;66(1):115-119. 
12. Böttiger L, Westholm B. Aplastic anaemia. I. Incidence and aetiology. 
Acta Med Scand. 1972;192(4):315-318. 
13. Davies S, Walker D. Aplastic anaemia in the Northern Region 1971-1978 
and follow-up of long term survivors. Clin lab Haemat. 1986;8:307-313. 
14. Cartwright RA, McKinney PA, Williams L, et al. Aplastic anaemia 
incidence in parts of the United Kingdom in 1985. Leuk Res. 
1988;12(6):459-463. 
15. Mary JY, Baumelou E, Guiguet M. Epidemiology of aplastic anemia in 
France: a prospective multicentric study. The French Cooperative Group 
for Epidemiological Study of Aplastic Anemia. Blood. 1990;75(8):1646-
1653. 
16. Montane E, Ibanez L, Vidal X, et al. Epidemiology of aplastic anemia: a 
prospective multicenter study. Haematologica. 2008;93(4):518-523. 
Aplastic anemia - a population-based study of epidemiology, treatment, and prognostic factors 
38 
17. Maluf E, Hamerschlak N, Cavalcanti AB, et al. Incidence and risk factors 
of aplastic anemia in Latin American countries: the LATIN case-control 
study. Haematologica. 2009;94(9):1220-1226. 
18. Kojima S. Aplastic anemia in the Orient. Int J Hematol. 2002;76 Suppl 
2:173-174. 
19. Issaragrisil S, Kaufman DW, Anderson T, et al. The epidemiology of 
aplastic anemia in Thailand. Blood. 2006;107(4):1299-1307. 
20. Issaragrisil S, Sriratanasatavorn C, Piankijagum A, et al. Incidence of 
aplastic anemia in Bangkok. Blood. 1991;77(10):2166-2168. 
21. Yang C, Zhang X. Incidence survey of aplastic anemia in China. Chin 
Med Sci J. 1991;6(4):203-207. 
22. Jeong DC, Chung NG, Kang HJ, et al. Epidemiology and clinical long-
term outcome of childhood aplastic anemia in Korea for 15 years: 
retrospective study of the Korean Society of Pediatric Hematology 
Oncology (KSPHO). J Pediatr Hematol Oncol. 2011;33(3):172-178. 
23. Young NS, Maciejewski J. The Pathophysiology of Acquired Aplastic 
Anemia. N Engl J Med. 1997;336(19);1365-72. 
24. Kaufman DW, Kelly J, Jurgelon J, et al. Drugs in the aetiology of 
agranulocytosis and aplastic anaemia. Eur J Haematol. 
1996;57(suppl):23-30. 
25. Tesfa D, Keisu M, Palmblad J. Idiosyncratic drug-induced 
agranulocytosis: possible mechanisms and management. Am J Hematol. 
2009;84(7):428-434. 
26. Rauff B, Idrees M, Shah SA, et al. Hepatitis associated aplastic anemia: a 
review. Virol J. 2011;8:87. 
27. Young NS. Aplastic anaemia. Lancet. 1995;346:228-232. 
28. de Masson A, Bouaziz JD, Peffault de Latour R, et al. Severe aplastic 
anemia associated with eosinophilic fasciitis: report of 4 cases and review 
of the literature. Medicine (Baltimore). 2013;92(2):69-81. 
29. Toret E, Demirag B, Köker SA, et al. Aplastic Anemia as an Immune-
mediated Complication of Thymoma. J Pediatr Hematol Oncol. 
2018;40:e464-e466. 
30. Jagasia MH, Greinix HT, Arora M, et al. National Institutes of Health 
Consensus Development Project on Criteria for Clinical Trials in Chronic 
Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working 
Group report. Biol Blood Marrow Transplant. 2015;21(3):389-401 e381. 
31. Mathé G, Amiel JL, Schwarzenberg L, et al. Bone marrow graft in man 
after conditioning by antilymphocytic serum. Br J Haematol. 1970;2:131-
136. 
32. Hinterberger W, Rowlings P, Hinterberger-Fisher M, et al. Results of 
transplanting bone marrow from genetically identical twins into patients 
with aplastic anemia. Ann Intern Med. 1997;126:116-122. 
 
39 
33. Young NS, Calado RT, Scheinberg P. Current concepts in the 
pathophysiology and treatment of aplastic anemia. Blood. 
2006;108(8):2509-2519. 
34. Maciejewski JP, Selleri C, Sato T, Anderson S, Young NS. A severe and 
consistent deficit in marrow and circulating primitive hematopoietic cells 
(long-term culture-initiating cells) in acquired aplastic anemia. Blood. 
1996;88(6):1983-1991. 
35. Zoumbos NC, Gascón P, Djeu JY, Trost SR, Young NS. Circulating 
Activated Suppressor T Lymphocytes in Aplastic Anemia. New England 
Journal of Medicine. 1985;312(5):257-265. 
36. Hu X, Gu Y, Wang Y, Cong Y, Qu X, Xu C. Increased CD4+ and CD8+ 
effector memory T cells in patients with aplastic anemia. Haematologica. 
2009;94(3):428-429. 
37. Sheng W, Liu C, Fu R, et al. Abnormalities of quantities and functions of 
linker for activations of T cells in severe aplastic anemia. Eur J Haematol. 
2014;93(3):214-223. 
38. Hosokawa K, Muranski P, Feng X, et al. Memory Stem T Cells in 
Autoimmune Disease: High Frequency of Circulating CD8+ Memory 
Stem Cells in Acquired Aplastic Anemia. J Immunol. 2016;196(4):1568-
1578. 
39. Risitano AM. (Auto-)immune signature in aplastic anemia. 
Haematologica. 2018;103(5):747-749. 
40. Giudice V, Feng X, Lin Z, et al. Deep sequencing and flow cytometric 
characterization of expanded effector memory CD8(+)CD57(+) T cells 
frequently reveals T-cell receptor Vbeta oligoclonality and CDR3 
homology in acquired aplastic anemia. Haematologica. 2018;103(5):759-
769. 
41. Dufour C, Capasso M, Svahn J, et al. Homozygosis for (12) CA repeats 
in the first intron of the human IFN-gamma gene is significantly 
associated with the risk of aplastic anaemia in Caucasian population. Br J 
Haematol. 2004;126(5):682-685. 
42. Zoumbos N, Gascon P, Djeu J, Young N. Interferon  is a mediator of 
hematopoietic suppression in aplastic anemia in vitro and possibly in vivo. 
Proc Natl Sci U S A. 1985;82(1):188-192. 
43. Liu CY, Fu R, Wang HQ, et al. Fas/FasL in the immune pathogenesis of 
severe aplastic anemia. Genet Mol Res. 2014;13(2):4083-4088. 
44. Sun W WZ, Lin Z, Hollinger M, Chen J, Feng X, Young NS. Macrophage 
TNF-α licenses donor T cells in murine bone marrow failure and can be 
implicated in human aplastic anemia. Blood. 2018;132:2730-2743. 
45. Park M, Park CJ, Cho YW, et al. Alterations in the bone marrow 
microenvironment may elicit defective hematopoiesis: a comparison of 
aplastic anemia, chronic myeloid leukemia, and normal bone marrow. Exp 
Hematol. 2017;45:56-63. 
Aplastic anemia - a population-based study of epidemiology, treatment, and prognostic factors 
38 
17. Maluf E, Hamerschlak N, Cavalcanti AB, et al. Incidence and risk factors 
of aplastic anemia in Latin American countries: the LATIN case-control 
study. Haematologica. 2009;94(9):1220-1226. 
18. Kojima S. Aplastic anemia in the Orient. Int J Hematol. 2002;76 Suppl 
2:173-174. 
19. Issaragrisil S, Kaufman DW, Anderson T, et al. The epidemiology of 
aplastic anemia in Thailand. Blood. 2006;107(4):1299-1307. 
20. Issaragrisil S, Sriratanasatavorn C, Piankijagum A, et al. Incidence of 
aplastic anemia in Bangkok. Blood. 1991;77(10):2166-2168. 
21. Yang C, Zhang X. Incidence survey of aplastic anemia in China. Chin 
Med Sci J. 1991;6(4):203-207. 
22. Jeong DC, Chung NG, Kang HJ, et al. Epidemiology and clinical long-
term outcome of childhood aplastic anemia in Korea for 15 years: 
retrospective study of the Korean Society of Pediatric Hematology 
Oncology (KSPHO). J Pediatr Hematol Oncol. 2011;33(3):172-178. 
23. Young NS, Maciejewski J. The Pathophysiology of Acquired Aplastic 
Anemia. N Engl J Med. 1997;336(19);1365-72. 
24. Kaufman DW, Kelly J, Jurgelon J, et al. Drugs in the aetiology of 
agranulocytosis and aplastic anaemia. Eur J Haematol. 
1996;57(suppl):23-30. 
25. Tesfa D, Keisu M, Palmblad J. Idiosyncratic drug-induced 
agranulocytosis: possible mechanisms and management. Am J Hematol. 
2009;84(7):428-434. 
26. Rauff B, Idrees M, Shah SA, et al. Hepatitis associated aplastic anemia: a 
review. Virol J. 2011;8:87. 
27. Young NS. Aplastic anaemia. Lancet. 1995;346:228-232. 
28. de Masson A, Bouaziz JD, Peffault de Latour R, et al. Severe aplastic 
anemia associated with eosinophilic fasciitis: report of 4 cases and review 
of the literature. Medicine (Baltimore). 2013;92(2):69-81. 
29. Toret E, Demirag B, Köker SA, et al. Aplastic Anemia as an Immune-
mediated Complication of Thymoma. J Pediatr Hematol Oncol. 
2018;40:e464-e466. 
30. Jagasia MH, Greinix HT, Arora M, et al. National Institutes of Health 
Consensus Development Project on Criteria for Clinical Trials in Chronic 
Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working 
Group report. Biol Blood Marrow Transplant. 2015;21(3):389-401 e381. 
31. Mathé G, Amiel JL, Schwarzenberg L, et al. Bone marrow graft in man 
after conditioning by antilymphocytic serum. Br J Haematol. 1970;2:131-
136. 
32. Hinterberger W, Rowlings P, Hinterberger-Fisher M, et al. Results of 
transplanting bone marrow from genetically identical twins into patients 
with aplastic anemia. Ann Intern Med. 1997;126:116-122. 
 
39 
33. Young NS, Calado RT, Scheinberg P. Current concepts in the 
pathophysiology and treatment of aplastic anemia. Blood. 
2006;108(8):2509-2519. 
34. Maciejewski JP, Selleri C, Sato T, Anderson S, Young NS. A severe and 
consistent deficit in marrow and circulating primitive hematopoietic cells 
(long-term culture-initiating cells) in acquired aplastic anemia. Blood. 
1996;88(6):1983-1991. 
35. Zoumbos NC, Gascón P, Djeu JY, Trost SR, Young NS. Circulating 
Activated Suppressor T Lymphocytes in Aplastic Anemia. New England 
Journal of Medicine. 1985;312(5):257-265. 
36. Hu X, Gu Y, Wang Y, Cong Y, Qu X, Xu C. Increased CD4+ and CD8+ 
effector memory T cells in patients with aplastic anemia. Haematologica. 
2009;94(3):428-429. 
37. Sheng W, Liu C, Fu R, et al. Abnormalities of quantities and functions of 
linker for activations of T cells in severe aplastic anemia. Eur J Haematol. 
2014;93(3):214-223. 
38. Hosokawa K, Muranski P, Feng X, et al. Memory Stem T Cells in 
Autoimmune Disease: High Frequency of Circulating CD8+ Memory 
Stem Cells in Acquired Aplastic Anemia. J Immunol. 2016;196(4):1568-
1578. 
39. Risitano AM. (Auto-)immune signature in aplastic anemia. 
Haematologica. 2018;103(5):747-749. 
40. Giudice V, Feng X, Lin Z, et al. Deep sequencing and flow cytometric 
characterization of expanded effector memory CD8(+)CD57(+) T cells 
frequently reveals T-cell receptor Vbeta oligoclonality and CDR3 
homology in acquired aplastic anemia. Haematologica. 2018;103(5):759-
769. 
41. Dufour C, Capasso M, Svahn J, et al. Homozygosis for (12) CA repeats 
in the first intron of the human IFN-gamma gene is significantly 
associated with the risk of aplastic anaemia in Caucasian population. Br J 
Haematol. 2004;126(5):682-685. 
42. Zoumbos N, Gascon P, Djeu J, Young N. Interferon  is a mediator of 
hematopoietic suppression in aplastic anemia in vitro and possibly in vivo. 
Proc Natl Sci U S A. 1985;82(1):188-192. 
43. Liu CY, Fu R, Wang HQ, et al. Fas/FasL in the immune pathogenesis of 
severe aplastic anemia. Genet Mol Res. 2014;13(2):4083-4088. 
44. Sun W WZ, Lin Z, Hollinger M, Chen J, Feng X, Young NS. Macrophage 
TNF-α licenses donor T cells in murine bone marrow failure and can be 
implicated in human aplastic anemia. Blood. 2018;132:2730-2743. 
45. Park M, Park CJ, Cho YW, et al. Alterations in the bone marrow 
microenvironment may elicit defective hematopoiesis: a comparison of 
aplastic anemia, chronic myeloid leukemia, and normal bone marrow. Exp 
Hematol. 2017;45:56-63. 
Aplastic anemia - a population-based study of epidemiology, treatment, and prognostic factors 
40 
46. Smith JN, Kanwar VS, MacNamara KC. Hematopoietic Stem Cell 
Regulation by Type I and II Interferons in the Pathogenesis of Acquired 
Aplastic Anemia. Front Immunol. 2016;7:330. 
47. Yan L, Fu R, Liu H, et al. Abnormal quantity and function of regulatory 
T cells in peripheral blood of patients with severe aplastic anemia. Cell 
Immunol. 2015;296(2):95-105. 
48. Kordasti S, Costantini B, Seidl T, et al. Deep phenotyping of Tregs 
identifies an immune signature for idiopathic aplastic anemia and predicts 
response to treatment. Blood. 2016;128(9):1193-1205. 
49. Lin S, Hou L, Liu S, et al. Roles of regulatory T cells in the pathogenesis 
of pediatric aplastic anemia. Pediatr Hematol Oncol. 2019;36(4):198-
210. 
50. Hoyer KK, Kuswanto WF, Gallo E, Abbas AK. Distinct roles of helper 
T-cell subsets in a systemic autoimmune disease. Blood. 
2009;113(2):389-395. 
51. de Latour RP, Visconte V, Takaku T, et al. Th17 immune responses 
contribute to the pathophysiology of aplastic anemia. Blood. 
2010;116(20):4175-4184. 
52. Kordasti S, Marsh J, Al-Khan S, et al. Functional characterization of 
CD4+ T cells in aplastic anemia. Blood. 2012;119(9):2033-2043. 
53. Calado RT, Young NS. Telomere maintenance and human bone marrow 
failure. Blood. 2008;111(9):4446-4455. 
54. Scheinberg P, Cooper JN, Sloand EM, Wu CO, Calado RT, Young NS. 
Association of telomere length of peripheral blood leukocytes with 
hematopoietic relapse, malignant transformation, and survival in severe 
aplastic anemia. JAMA. 2010;304(12):1358-1364. 
55. Harrington L. Biochemical aspects of telomerase function. Cancer 
Letters. 2003;194(2):139-154. 
56. Yamaguchi H, Calado R, Ly H, et al. Mutations in TERT, the Gene for 
Telomerase Reverse Transcriptase, in Aplastic Anemia. N Engl J Med. 
2005;352:1413-1424. 
57. Ball SE, Gibson FM, Rizzo S, Tooze JA, Marsh J, Gordon-Smith EC. 
Progressive telomere shortening  in aplastic anemia. Blood. 
1998;91(10):3582-3592. 
58. Mitchell JR, Wood E, Collins K. A telomerase component is defective in 
the human disease dyskeratosis congenita. Nature. 1999;402:551-555. 
59. Thornley I, Dror Y, Sung L, Wynn R, Freedman MH. Abnormal telomere 
shortening in leucocytes of children with Shwachman-Diamond 
syndrome. Br J Haematol. 2002;117:189-192. 
60. Calado RT, Young NS. Telomere diseases. N Engl J Med. 
2009;361(24):2353-2365. 
61. Cooper JN, Young NS. Clonality in context: hematopoietic clones in their 
marrow environment. Blood. 2017;130(22):2363-2372. 
 
41 
62. Babushok DV. A brief, but comprehensive, guide to clonal evolution in 
aplastic anemia. Hematology Am Soc Hematol Educ Program. 
2018;2018(1):457-466. 
63. Li Y, Li X, Ge M, et al. Long-term follow-up of clonal evolutions in 802 
aplastic anemia patients: a single-center experience. Ann Hematol. 
2011;90(5):529-537. 
64. Socie G, Henry-Amar M, Bacigalupo A, et al. Malignant tumors 
occurring after treatment of aplastic anemia. European Bone Marrow 
Transplantation-Severe Aplastic Anaemia Working Party. N Engl J Med. 
1993;329(16):1152-1157. 
65. Najean Y, Haguenauer O, Anaemias ftCGftSoAaR. Long-term (5 to 20 
years) Evolution of nongrafted aplastic anemias. The Cooperative Group 
for the Study of Aplastic and Refractory Anemias. Blood. 
1990;76(11):2222-2228. 
66. Scheinberg P, Wu CO, Nunez O, Young NS. Long-term outcome of 
pediatric patients with severe aplastic anemia treated with antithymocyte 
globulin and cyclosporine. J Pediatr. 2008;153(6):814-819. 
67. Tichelli A, Peffault de Latour R, Passweg J, et al. Long-term outcome of 
a randomized controlled study in patients with newly diagnosed severe 
aplastic anemia treated with antithymocyte globuline, cyclosporine, with 
or without G-CSF: a Severe Aplastic Anemia Working Party Trial from 
the European Group of Blood and Marrow Transplantation. 
Haematologica. 2020;105(5):1223-1231. 
68. Maciejewski JP, Selleri C. Evolution Of Clonal Cytogenetic 
Abnormalities in Aplastic Anemia. Leukemia & Lymphoma. 
2004;45(3):433-440. 
69. Geary CG, Harrison CJ, Philpott NJ, Hows JM, Gordon-Smith EC, Marsh 
JCW. Abnormal cytogenetic clones in patients with aplastic anaemia: 
response to immunosuppressive therapy. British Journal of Haematology. 
1999;104(2):271-274. 
70. Maciejewski JP, Risitano A, Sloand EM, Nunez O, Young NS. Distinct 
clinical outcomes for cytogenetic abnormalities evolving from aplastic 
anemia. Blood. 2002;99(9):3129-3135. 
71. Gupta V, Brooker C, Tooze JA, et al. Clinical relevance of cytogenetic 
abnormalities at diagnosis of acquired aplastic anaemia in adults. Br J 
Haematol. 2006;134(1):95-99. 
72. Yoshizato T, Dumitriu B, Hosokawa K, et al. Somatic Mutations and 
Clonal Hematopoiesis in Aplastic Anemia. N Engl J Med. 
2015;373(1):35-47. 
73. Kulasekararaj AG, Jiang J, Smith AE, et al. Somatic mutations identify a 
subgroup of aplastic anemia patients who progress to myelodysplastic 
syndrome. Blood. 2014;124(17):2698-2704. 
Aplastic anemia - a population-based study of epidemiology, treatment, and prognostic factors 
40 
46. Smith JN, Kanwar VS, MacNamara KC. Hematopoietic Stem Cell 
Regulation by Type I and II Interferons in the Pathogenesis of Acquired 
Aplastic Anemia. Front Immunol. 2016;7:330. 
47. Yan L, Fu R, Liu H, et al. Abnormal quantity and function of regulatory 
T cells in peripheral blood of patients with severe aplastic anemia. Cell 
Immunol. 2015;296(2):95-105. 
48. Kordasti S, Costantini B, Seidl T, et al. Deep phenotyping of Tregs 
identifies an immune signature for idiopathic aplastic anemia and predicts 
response to treatment. Blood. 2016;128(9):1193-1205. 
49. Lin S, Hou L, Liu S, et al. Roles of regulatory T cells in the pathogenesis 
of pediatric aplastic anemia. Pediatr Hematol Oncol. 2019;36(4):198-
210. 
50. Hoyer KK, Kuswanto WF, Gallo E, Abbas AK. Distinct roles of helper 
T-cell subsets in a systemic autoimmune disease. Blood. 
2009;113(2):389-395. 
51. de Latour RP, Visconte V, Takaku T, et al. Th17 immune responses 
contribute to the pathophysiology of aplastic anemia. Blood. 
2010;116(20):4175-4184. 
52. Kordasti S, Marsh J, Al-Khan S, et al. Functional characterization of 
CD4+ T cells in aplastic anemia. Blood. 2012;119(9):2033-2043. 
53. Calado RT, Young NS. Telomere maintenance and human bone marrow 
failure. Blood. 2008;111(9):4446-4455. 
54. Scheinberg P, Cooper JN, Sloand EM, Wu CO, Calado RT, Young NS. 
Association of telomere length of peripheral blood leukocytes with 
hematopoietic relapse, malignant transformation, and survival in severe 
aplastic anemia. JAMA. 2010;304(12):1358-1364. 
55. Harrington L. Biochemical aspects of telomerase function. Cancer 
Letters. 2003;194(2):139-154. 
56. Yamaguchi H, Calado R, Ly H, et al. Mutations in TERT, the Gene for 
Telomerase Reverse Transcriptase, in Aplastic Anemia. N Engl J Med. 
2005;352:1413-1424. 
57. Ball SE, Gibson FM, Rizzo S, Tooze JA, Marsh J, Gordon-Smith EC. 
Progressive telomere shortening  in aplastic anemia. Blood. 
1998;91(10):3582-3592. 
58. Mitchell JR, Wood E, Collins K. A telomerase component is defective in 
the human disease dyskeratosis congenita. Nature. 1999;402:551-555. 
59. Thornley I, Dror Y, Sung L, Wynn R, Freedman MH. Abnormal telomere 
shortening in leucocytes of children with Shwachman-Diamond 
syndrome. Br J Haematol. 2002;117:189-192. 
60. Calado RT, Young NS. Telomere diseases. N Engl J Med. 
2009;361(24):2353-2365. 
61. Cooper JN, Young NS. Clonality in context: hematopoietic clones in their 
marrow environment. Blood. 2017;130(22):2363-2372. 
 
41 
62. Babushok DV. A brief, but comprehensive, guide to clonal evolution in 
aplastic anemia. Hematology Am Soc Hematol Educ Program. 
2018;2018(1):457-466. 
63. Li Y, Li X, Ge M, et al. Long-term follow-up of clonal evolutions in 802 
aplastic anemia patients: a single-center experience. Ann Hematol. 
2011;90(5):529-537. 
64. Socie G, Henry-Amar M, Bacigalupo A, et al. Malignant tumors 
occurring after treatment of aplastic anemia. European Bone Marrow 
Transplantation-Severe Aplastic Anaemia Working Party. N Engl J Med. 
1993;329(16):1152-1157. 
65. Najean Y, Haguenauer O, Anaemias ftCGftSoAaR. Long-term (5 to 20 
years) Evolution of nongrafted aplastic anemias. The Cooperative Group 
for the Study of Aplastic and Refractory Anemias. Blood. 
1990;76(11):2222-2228. 
66. Scheinberg P, Wu CO, Nunez O, Young NS. Long-term outcome of 
pediatric patients with severe aplastic anemia treated with antithymocyte 
globulin and cyclosporine. J Pediatr. 2008;153(6):814-819. 
67. Tichelli A, Peffault de Latour R, Passweg J, et al. Long-term outcome of 
a randomized controlled study in patients with newly diagnosed severe 
aplastic anemia treated with antithymocyte globuline, cyclosporine, with 
or without G-CSF: a Severe Aplastic Anemia Working Party Trial from 
the European Group of Blood and Marrow Transplantation. 
Haematologica. 2020;105(5):1223-1231. 
68. Maciejewski JP, Selleri C. Evolution Of Clonal Cytogenetic 
Abnormalities in Aplastic Anemia. Leukemia & Lymphoma. 
2004;45(3):433-440. 
69. Geary CG, Harrison CJ, Philpott NJ, Hows JM, Gordon-Smith EC, Marsh 
JCW. Abnormal cytogenetic clones in patients with aplastic anaemia: 
response to immunosuppressive therapy. British Journal of Haematology. 
1999;104(2):271-274. 
70. Maciejewski JP, Risitano A, Sloand EM, Nunez O, Young NS. Distinct 
clinical outcomes for cytogenetic abnormalities evolving from aplastic 
anemia. Blood. 2002;99(9):3129-3135. 
71. Gupta V, Brooker C, Tooze JA, et al. Clinical relevance of cytogenetic 
abnormalities at diagnosis of acquired aplastic anaemia in adults. Br J 
Haematol. 2006;134(1):95-99. 
72. Yoshizato T, Dumitriu B, Hosokawa K, et al. Somatic Mutations and 
Clonal Hematopoiesis in Aplastic Anemia. N Engl J Med. 
2015;373(1):35-47. 
73. Kulasekararaj AG, Jiang J, Smith AE, et al. Somatic mutations identify a 
subgroup of aplastic anemia patients who progress to myelodysplastic 
syndrome. Blood. 2014;124(17):2698-2704. 
Aplastic anemia - a population-based study of epidemiology, treatment, and prognostic factors 
42 
74. Luzzatto L. Recent advances in the pathogenesis and treatment of 
paroxysmal nocturnal hemoglobinuria. F1000Research. 2016;5:F1000 
Faculty Rev-1209. 
75. Hill A, DeZern AE, Kinoshita T, Brodsky RA. Paroxysmal nocturnal 
haemoglobinuria. Nature Reviews Disease Primers. 2017;3(1):17028. 
76. Pu JJ, Mukhina G, Wang H, Savage WJ, Brodsky RA. Natural history of 
paroxysmal nocturnal hemoglobinuria clones in patients presenting as 
aplastic anemia. European Journal of Haematology. 2011;87(1):37-45. 
77. Frickhofen N, Heimpel H, Kaltwasser JP, Schrezenmeier H. 
Antithymocyte globulin with or without cyclosporin A: 11-year follow-
up of a randomized trial comparing treatments of aplastic anemia. Blood. 
2003;101(4):1236-1242. 
78. Rosenfeld S, Follmann D, Nunez O, Young NS. Antithymocyte globulin 
and cyclosporine for severe aplastic anemia: association between 
hematologic response and long-term outcome. JAMA. 2003;289(9):1130-
1135. 
79. Tichelli A, Schrezenmeier H, Socie G, et al. A randomized controlled 
study in patients with newly diagnosed severe aplastic anemia receiving 
antithymocyte globulin (ATG), cyclosporine, with or without G-CSF: a 
study of the SAA Working Party of the European Group for Blood and 
Marrow Transplantation. Blood. 2011;117(17):4434-4441. 
80. de Planque MM, Bacigalupo A, Würsch A, et al. Long-term follow-up of 
severe aplastic anaemia patients treated with antithymocyte globulin. 
British Journal of Haematology. 1989;73(1):121-126. 
81. Socié G, Schrezenmeier H, Muus P, et al. Changing prognosis in 
paroxysmal nocturnal haemoglobinuria disease subcategories: an analysis 
of the International PNH Registry. Internal Medicine Journal. 
2016;46(9):1044-1053. 
82. Deng XZ, Du M, Peng J, et al. Associations between the HLA-A/B/DRB1 
polymorphisms and aplastic anemia: evidence from 17 case-control 
studies. Hematology. 2018;23(3):154-162. 
83. Katagiri T, Sato-Otsubo A, Kashiwase K, et al. Frequent loss of HLA 
alleles associated with copy number-neutral 6pLOH in acquired aplastic 
anemia. Blood. 2011;118(25):6601-6609. 
84. Afable MG, II, Wlodarski M, Makishima H, et al. SNP array–based 
karyotyping: differences and similarities between aplastic anemia and 
hypocellular myelodysplastic syndromes. Blood. 2011;117(25):6876-
6884. 
85. Betensky M, Babushok D, Roth JJ, et al. Clonal evolution and clinical 
significance of copy number neutral loss of heterozygosity of 
chromosome arm 6p in acquired aplastic anemia. Cancer Genet. 
2016;209(1-2):1-10. 
 
43 
86. Babushok DV, Duke JL, Xie HM, et al. Somatic HLA mutations expose 
the role of class I–mediated autoimmunity in aplastic anemia and its 
clonal complications. Blood Advances. 2017;1(22):1900-1910. 
87. Alter BP. Diagnosis, Genetics, and Management of Inherited Bone 
Marrow Failure Syndromes. Hematology. 2007;2007(1):29-39. 
88. de Winter JP, Joenje H. The genetic and molecular basis of Fanconi 
anemia. Mutat Res. 2009;668(1-2):11-19. 
89. Shimamura A. Aplastic anemia and clonal evolution: germ line and 
somatic genetics. Hematology Am Soc Hematol Educ Program. 
2016;2016(1):74-82. 
90. Soulier J. Fanconi Anemia. Hematology Am Soc Hematol Educ Program. 
2011;2011(1):492-497. 
91. Kutler DI, Singh B, Satagopan J, et al. A 20-year perspective on the 
International Fanconi Anemia Registry (IFAR). Blood. 
2003;101(4):1249-1256. 
92. Rosenberg PS, Greene MH, Alter BP. Cancer incidence in persons with 
Fanconi anemia. Blood. 2003;101(3):822-826. 
93. Dokal I. Dyskeratosis Congenita. Hematology Am Soc Hematol Educ 
Program. 2011;2011(1):480-486. 
94. Alter BP. Inherited bone marrow failure syndromes: considerations pre- 
and posttransplant. Hematology Am Soc Hematol Educ Program. 
2017;2017(1):88-95. 
95. Crispino JD, Horwitz MS. GATA factor mutations in hematologic 
disease. Blood. 2017;129(15):2103-2110. 
96. Hsu AP, McReynolds LJ, Holland SM. GATA2 deficiency. Curr Opin 
Allergy Clin Immunol. 2015;15(1):104-109. 
97. Spinner MA, Sanchez LA, Hsu AP, et al. GATA2 deficiency: a protean 
disorder of hematopoiesis, lymphatics, and immunity. Blood. 
2014;123(6):809-821. 
98. Ganapathi KA, Townsley DM, Hsu AP, et al. GATA2 deficiency-
associated bone marrow disorder differs from idiopathic aplastic anemia. 
Blood. 2015;125(1):56-70. 
99. Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World 
Health Organization classification of myeloid neoplasms and acute 
leukemia. Blood. 2016;127(20):2391-2405. 
100. Maschek H, Kaloutsi V, Rodriguez-Kaiser M, et al. Hypoplastic 
myelodysplastic syndrome: incidence, morphology, cytogenetics, and 
prognosis. Annals of Hematology. 1993;66(3):117-122. 
101. Geary CG, Marsh JC, Gordon-Smith EC. Hypoplastic myelodysplasia 
(MDS). Br J Haematol. 1996;94(3):582-583. 
102. Stanley N, Olson TS, Babushok DV. Recent advances in understanding 
clonal haematopoiesis in aplastic anaemia. Br J Haematol. 
2017;177(4):509-525. 
Aplastic anemia - a population-based study of epidemiology, treatment, and prognostic factors 
42 
74. Luzzatto L. Recent advances in the pathogenesis and treatment of 
paroxysmal nocturnal hemoglobinuria. F1000Research. 2016;5:F1000 
Faculty Rev-1209. 
75. Hill A, DeZern AE, Kinoshita T, Brodsky RA. Paroxysmal nocturnal 
haemoglobinuria. Nature Reviews Disease Primers. 2017;3(1):17028. 
76. Pu JJ, Mukhina G, Wang H, Savage WJ, Brodsky RA. Natural history of 
paroxysmal nocturnal hemoglobinuria clones in patients presenting as 
aplastic anemia. European Journal of Haematology. 2011;87(1):37-45. 
77. Frickhofen N, Heimpel H, Kaltwasser JP, Schrezenmeier H. 
Antithymocyte globulin with or without cyclosporin A: 11-year follow-
up of a randomized trial comparing treatments of aplastic anemia. Blood. 
2003;101(4):1236-1242. 
78. Rosenfeld S, Follmann D, Nunez O, Young NS. Antithymocyte globulin 
and cyclosporine for severe aplastic anemia: association between 
hematologic response and long-term outcome. JAMA. 2003;289(9):1130-
1135. 
79. Tichelli A, Schrezenmeier H, Socie G, et al. A randomized controlled 
study in patients with newly diagnosed severe aplastic anemia receiving 
antithymocyte globulin (ATG), cyclosporine, with or without G-CSF: a 
study of the SAA Working Party of the European Group for Blood and 
Marrow Transplantation. Blood. 2011;117(17):4434-4441. 
80. de Planque MM, Bacigalupo A, Würsch A, et al. Long-term follow-up of 
severe aplastic anaemia patients treated with antithymocyte globulin. 
British Journal of Haematology. 1989;73(1):121-126. 
81. Socié G, Schrezenmeier H, Muus P, et al. Changing prognosis in 
paroxysmal nocturnal haemoglobinuria disease subcategories: an analysis 
of the International PNH Registry. Internal Medicine Journal. 
2016;46(9):1044-1053. 
82. Deng XZ, Du M, Peng J, et al. Associations between the HLA-A/B/DRB1 
polymorphisms and aplastic anemia: evidence from 17 case-control 
studies. Hematology. 2018;23(3):154-162. 
83. Katagiri T, Sato-Otsubo A, Kashiwase K, et al. Frequent loss of HLA 
alleles associated with copy number-neutral 6pLOH in acquired aplastic 
anemia. Blood. 2011;118(25):6601-6609. 
84. Afable MG, II, Wlodarski M, Makishima H, et al. SNP array–based 
karyotyping: differences and similarities between aplastic anemia and 
hypocellular myelodysplastic syndromes. Blood. 2011;117(25):6876-
6884. 
85. Betensky M, Babushok D, Roth JJ, et al. Clonal evolution and clinical 
significance of copy number neutral loss of heterozygosity of 
chromosome arm 6p in acquired aplastic anemia. Cancer Genet. 
2016;209(1-2):1-10. 
 
43 
86. Babushok DV, Duke JL, Xie HM, et al. Somatic HLA mutations expose 
the role of class I–mediated autoimmunity in aplastic anemia and its 
clonal complications. Blood Advances. 2017;1(22):1900-1910. 
87. Alter BP. Diagnosis, Genetics, and Management of Inherited Bone 
Marrow Failure Syndromes. Hematology. 2007;2007(1):29-39. 
88. de Winter JP, Joenje H. The genetic and molecular basis of Fanconi 
anemia. Mutat Res. 2009;668(1-2):11-19. 
89. Shimamura A. Aplastic anemia and clonal evolution: germ line and 
somatic genetics. Hematology Am Soc Hematol Educ Program. 
2016;2016(1):74-82. 
90. Soulier J. Fanconi Anemia. Hematology Am Soc Hematol Educ Program. 
2011;2011(1):492-497. 
91. Kutler DI, Singh B, Satagopan J, et al. A 20-year perspective on the 
International Fanconi Anemia Registry (IFAR). Blood. 
2003;101(4):1249-1256. 
92. Rosenberg PS, Greene MH, Alter BP. Cancer incidence in persons with 
Fanconi anemia. Blood. 2003;101(3):822-826. 
93. Dokal I. Dyskeratosis Congenita. Hematology Am Soc Hematol Educ 
Program. 2011;2011(1):480-486. 
94. Alter BP. Inherited bone marrow failure syndromes: considerations pre- 
and posttransplant. Hematology Am Soc Hematol Educ Program. 
2017;2017(1):88-95. 
95. Crispino JD, Horwitz MS. GATA factor mutations in hematologic 
disease. Blood. 2017;129(15):2103-2110. 
96. Hsu AP, McReynolds LJ, Holland SM. GATA2 deficiency. Curr Opin 
Allergy Clin Immunol. 2015;15(1):104-109. 
97. Spinner MA, Sanchez LA, Hsu AP, et al. GATA2 deficiency: a protean 
disorder of hematopoiesis, lymphatics, and immunity. Blood. 
2014;123(6):809-821. 
98. Ganapathi KA, Townsley DM, Hsu AP, et al. GATA2 deficiency-
associated bone marrow disorder differs from idiopathic aplastic anemia. 
Blood. 2015;125(1):56-70. 
99. Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World 
Health Organization classification of myeloid neoplasms and acute 
leukemia. Blood. 2016;127(20):2391-2405. 
100. Maschek H, Kaloutsi V, Rodriguez-Kaiser M, et al. Hypoplastic 
myelodysplastic syndrome: incidence, morphology, cytogenetics, and 
prognosis. Annals of Hematology. 1993;66(3):117-122. 
101. Geary CG, Marsh JC, Gordon-Smith EC. Hypoplastic myelodysplasia 
(MDS). Br J Haematol. 1996;94(3):582-583. 
102. Stanley N, Olson TS, Babushok DV. Recent advances in understanding 
clonal haematopoiesis in aplastic anaemia. Br J Haematol. 
2017;177(4):509-525. 
Aplastic anemia - a population-based study of epidemiology, treatment, and prognostic factors 
44 
103. Cremers EMP, Westers TM, Alhan C, et al. Multiparameter flow 
cytometry is instrumental to distinguish myelodysplastic syndromes from 
non-neoplastic cytopenias. European Journal of Cancer. 2016;54:49-56. 
104. Bennett JM, Orazi A. Diagnostic criteria to distinguish hypocellular acute 
myeloid leukemia from hypocellular myelodysplastic syndromes and 
aplastic anemia: recommendations for a standardized approach. 
Haematologica. 2009;94(2):264-268. 
105. Orazi A, Albitar M, Heerema N, Haskins S, Neiman R. Hypoplastic 
Myelodysplastic Syndromes Can Be Distinguished From Acquired 
Aplastic Anemia by CD34 and PCNA Immunostaining of Bone Marrow 
Biopsy Specimens. Am J Clin Pathol. 1997;107(3):268-274. 
106. Bono E, McLornan D, Travaglino E, et al. Clinical, histopathological and 
molecular characterization of hypoplastic myelodysplastic syndrome. 
Leukemia. 2019;33(10):2495-2505. 
107. Malcovati L, Galli A, Travaglino E, et al. Clinical significance of somatic 
mutation in unexplained blood cytopenia. Blood. 2017;129(25):3371-
3378. 
108. Koh Y, Lee HR, Song EY, et al. Hypoplastic myelodysplastic syndrome 
(h-MDS) is a distinctive clinical entity with poorer prognosis and frequent 
karyotypic and FISH abnormalities compared to aplastic anemia (AA). 
Leuk Res. 2010;34(10):1344-1350. 
109. Niemeyer CM, Baumann I. Classification of Childhood Aplastic Anemia 
and Myelodysplastic Syndrome. Hematology Am Soc Hematol Educ 
Program. 2011;2011(1):84-89. 
110. Keel SB, Scott A, Sanchez-Bonilla M, et al. Genetic features of 
myelodysplastic syndrome and aplastic anemia in pediatric and young 
adult patients. Haematologica. 2016;101(11):1343-1350. 
111. Kwon JH, Kim I, Lee YG, et al. Clinical course of non-severe aplastic 
anemia in adults. Int J Hematol. 2010;91(5):770-775. 
112. Lee J, Lee J, Shin Y, et al. Spontaneous remission of aplastic anemia: a 
retrospective analysis. Haematologica. 2001;86(9):928-933. 
113. Killick SB, Bown N, Cavenagh J, et al. Guidelines for the diagnosis and 
management of adult aplastic anaemia. Br J Haematol. 2016;172(2):187-
207. 
114. Bacigalupo A. How I treat acquired aplastic anemia. Blood. 
2017;129(11):1428-1434. 
115. Locasciulli A, Oneto R, Bacigalupo A, et al. Outcome of patients with 
acquired aplastic anemia given first line bone marrow transplantation or 
immunosuppressive treatment in the last decade: a report from the 
European Group for Blood and Marrow Transplantation (EBMT). 
Haematologica. 2007;92(1):11-18. 
116. Grube M, Holler E, Weber D, Holler B, Herr W, Wolff D. Risk Factors 
and Outcome of Chronic Graft-versus-Host Disease after Allogeneic 
 
45 
Stem Cell Transplantation-Results from a Single-Center Observational 
Study. Biol Blood Marrow Transplant. 2016;22(10):1781-1791. 
117. Kilgour JM, Wali G, Gibbons E, et al. Systematic Review of Patient-
Reported Outcome Measures in Graft-versus-Host Disease. Biology of 
Blood and Marrow Transplantation. 2020;26(5):e113-e127. 
118. Bacigalupo A, Brand R, Oneto R, et al. Treatment of acquired severe 
aplastic anemia: bone marrow transplantation compared with 
immunosuppressive therapy--The European Group for Blood and Marrow 
Transplantation experience. Semin Hematol. 2000;37(1):69-80. 
119. Bacigalupo A, Giammarco S, Sica S. Bone marrow transplantation versus 
immunosuppressive therapy in patients with acquired severe aplastic 
anemia. Int J Hematol. 2016;104(2):168-174. 
120. Giammarco S, Peffault de Latour R, Sica S, et al. Transplant outcome for 
patients with acquired aplastic anemia over the age of 40: has the outcome 
improved? Blood. 2018;131(17):1989-1992. 
121. Rice C, Eikema DJ, Marsh JCW, et al. Allogeneic Hematopoietic Cell 
Transplantation in Patients Aged 50Years or Older with Severe Aplastic 
Anemia. Biol Blood Marrow Transplant. 2019;25(3):488-495. 
122. Gupta V, Eapen M, Brazauskas R, et al. Impact of age on outcomes after 
bone marrow transplantation for acquired aplastic anemia using HLA-
matched sibling donors. Haematologica. 2010;95(12):2119-2125. 
123. Maury S, Bacigalupo A, Anderlini P, et al. Improved outcome of patients 
older than 30 years receiving HLA-identical sibling hematopoietic stem 
cell transplantation for severe acquired aplastic anemia using fludarabine-
based conditioning: a comparison with conventional conditioning 
regimen. Haematologica. 2009;94(9):1312-1315. 
124. Schrezenmeier H, Passweg JR, Marsh JCW, et al. Worse outcome and 
more chronic GVHD with peripheral blood progenitor cells than bone 
marrow in HLA-matched sibling donor transplants for young patients 
with severe acquired aplastic anemia. Blood. 2007;110(4):1397-1400. 
125. Bacigalupo A, Socie G, Schrezenmeier H, et al. Bone marrow versus 
peripheral blood as the stem cell source for sibling transplants in acquired 
aplastic anemia: survival advantage for bone marrow in all age groups. 
Haematologica. 2012;97(8):1142-1148. 
126. Hows JM, Yin JL, Marsh J, et al. Histocompatible unrelated volunteer 
donors compared with HLA nonidentical family donors in marrow 
transplantation for aplastic anemia and leukemia. Blood. 
1986;68(6):1322-1328. 
127. Kernan NA, Bartsch G, Ash RC, et al. Analysis of 462 transplantations 
from unrelated donors facilitated by the National Marrow Donor Program. 
N Engl J Med. 1993;328(9):593-602. 
128. Kojima S, Inaba J, Yoshimi A, et al. Unrelated donor marrow 
transplantation in children with severe aplastic anaemia using 
Aplastic anemia - a population-based study of epidemiology, treatment, and prognostic factors 
44 
103. Cremers EMP, Westers TM, Alhan C, et al. Multiparameter flow 
cytometry is instrumental to distinguish myelodysplastic syndromes from 
non-neoplastic cytopenias. European Journal of Cancer. 2016;54:49-56. 
104. Bennett JM, Orazi A. Diagnostic criteria to distinguish hypocellular acute 
myeloid leukemia from hypocellular myelodysplastic syndromes and 
aplastic anemia: recommendations for a standardized approach. 
Haematologica. 2009;94(2):264-268. 
105. Orazi A, Albitar M, Heerema N, Haskins S, Neiman R. Hypoplastic 
Myelodysplastic Syndromes Can Be Distinguished From Acquired 
Aplastic Anemia by CD34 and PCNA Immunostaining of Bone Marrow 
Biopsy Specimens. Am J Clin Pathol. 1997;107(3):268-274. 
106. Bono E, McLornan D, Travaglino E, et al. Clinical, histopathological and 
molecular characterization of hypoplastic myelodysplastic syndrome. 
Leukemia. 2019;33(10):2495-2505. 
107. Malcovati L, Galli A, Travaglino E, et al. Clinical significance of somatic 
mutation in unexplained blood cytopenia. Blood. 2017;129(25):3371-
3378. 
108. Koh Y, Lee HR, Song EY, et al. Hypoplastic myelodysplastic syndrome 
(h-MDS) is a distinctive clinical entity with poorer prognosis and frequent 
karyotypic and FISH abnormalities compared to aplastic anemia (AA). 
Leuk Res. 2010;34(10):1344-1350. 
109. Niemeyer CM, Baumann I. Classification of Childhood Aplastic Anemia 
and Myelodysplastic Syndrome. Hematology Am Soc Hematol Educ 
Program. 2011;2011(1):84-89. 
110. Keel SB, Scott A, Sanchez-Bonilla M, et al. Genetic features of 
myelodysplastic syndrome and aplastic anemia in pediatric and young 
adult patients. Haematologica. 2016;101(11):1343-1350. 
111. Kwon JH, Kim I, Lee YG, et al. Clinical course of non-severe aplastic 
anemia in adults. Int J Hematol. 2010;91(5):770-775. 
112. Lee J, Lee J, Shin Y, et al. Spontaneous remission of aplastic anemia: a 
retrospective analysis. Haematologica. 2001;86(9):928-933. 
113. Killick SB, Bown N, Cavenagh J, et al. Guidelines for the diagnosis and 
management of adult aplastic anaemia. Br J Haematol. 2016;172(2):187-
207. 
114. Bacigalupo A. How I treat acquired aplastic anemia. Blood. 
2017;129(11):1428-1434. 
115. Locasciulli A, Oneto R, Bacigalupo A, et al. Outcome of patients with 
acquired aplastic anemia given first line bone marrow transplantation or 
immunosuppressive treatment in the last decade: a report from the 
European Group for Blood and Marrow Transplantation (EBMT). 
Haematologica. 2007;92(1):11-18. 
116. Grube M, Holler E, Weber D, Holler B, Herr W, Wolff D. Risk Factors 
and Outcome of Chronic Graft-versus-Host Disease after Allogeneic 
 
45 
Stem Cell Transplantation-Results from a Single-Center Observational 
Study. Biol Blood Marrow Transplant. 2016;22(10):1781-1791. 
117. Kilgour JM, Wali G, Gibbons E, et al. Systematic Review of Patient-
Reported Outcome Measures in Graft-versus-Host Disease. Biology of 
Blood and Marrow Transplantation. 2020;26(5):e113-e127. 
118. Bacigalupo A, Brand R, Oneto R, et al. Treatment of acquired severe 
aplastic anemia: bone marrow transplantation compared with 
immunosuppressive therapy--The European Group for Blood and Marrow 
Transplantation experience. Semin Hematol. 2000;37(1):69-80. 
119. Bacigalupo A, Giammarco S, Sica S. Bone marrow transplantation versus 
immunosuppressive therapy in patients with acquired severe aplastic 
anemia. Int J Hematol. 2016;104(2):168-174. 
120. Giammarco S, Peffault de Latour R, Sica S, et al. Transplant outcome for 
patients with acquired aplastic anemia over the age of 40: has the outcome 
improved? Blood. 2018;131(17):1989-1992. 
121. Rice C, Eikema DJ, Marsh JCW, et al. Allogeneic Hematopoietic Cell 
Transplantation in Patients Aged 50Years or Older with Severe Aplastic 
Anemia. Biol Blood Marrow Transplant. 2019;25(3):488-495. 
122. Gupta V, Eapen M, Brazauskas R, et al. Impact of age on outcomes after 
bone marrow transplantation for acquired aplastic anemia using HLA-
matched sibling donors. Haematologica. 2010;95(12):2119-2125. 
123. Maury S, Bacigalupo A, Anderlini P, et al. Improved outcome of patients 
older than 30 years receiving HLA-identical sibling hematopoietic stem 
cell transplantation for severe acquired aplastic anemia using fludarabine-
based conditioning: a comparison with conventional conditioning 
regimen. Haematologica. 2009;94(9):1312-1315. 
124. Schrezenmeier H, Passweg JR, Marsh JCW, et al. Worse outcome and 
more chronic GVHD with peripheral blood progenitor cells than bone 
marrow in HLA-matched sibling donor transplants for young patients 
with severe acquired aplastic anemia. Blood. 2007;110(4):1397-1400. 
125. Bacigalupo A, Socie G, Schrezenmeier H, et al. Bone marrow versus 
peripheral blood as the stem cell source for sibling transplants in acquired 
aplastic anemia: survival advantage for bone marrow in all age groups. 
Haematologica. 2012;97(8):1142-1148. 
126. Hows JM, Yin JL, Marsh J, et al. Histocompatible unrelated volunteer 
donors compared with HLA nonidentical family donors in marrow 
transplantation for aplastic anemia and leukemia. Blood. 
1986;68(6):1322-1328. 
127. Kernan NA, Bartsch G, Ash RC, et al. Analysis of 462 transplantations 
from unrelated donors facilitated by the National Marrow Donor Program. 
N Engl J Med. 1993;328(9):593-602. 
128. Kojima S, Inaba J, Yoshimi A, et al. Unrelated donor marrow 
transplantation in children with severe aplastic anaemia using 
Aplastic anemia - a population-based study of epidemiology, treatment, and prognostic factors 
46 
cyclophosphamide, anti-thymocyte globulin and total body irradiation. Br 
J Haematol. 2001;114(3):706-711. 
129. Margolis D, Camitta B, Pietryga D, et al. Unrelated donor bone marrow 
transplantation to treat severe aplastic anaemia in children and young 
adults. Br J Haematol. 1996;94(1):65-72. 
130. Bacigalupo A, Socie G, Lanino E, et al. Fludarabine, cyclophosphamide, 
antithymocyte globulin, with or without low dose total body irradiation, 
for alternative donor transplants, in acquired severe aplastic anemia: a 
retrospective study from the EBMT-SAA Working Party. 
Haematologica. 2010;95(6):976-982. 
131. Socie G. Allogeneic BM transplantation for the treatment of aplastic 
anemia: current results and expanding donor possibilities. Hematology 
Am Soc Hematol Educ Program.2013; 2013(1):82-86. 
132. Maury S, Balere-Appert ML, Pollichieni S, et al. Outcome of patients 
activating an unrelated donor search for severe acquired aplastic anemia. 
Am J Hematol. 2013;88(10):868-873. 
133. Marsh JC, Gupta V, Lim Z, et al. Alemtuzumab with fludarabine and 
cyclophosphamide reduces chronic graft-versus-host disease after 
allogeneic stem cell transplantation for acquired aplastic anemia. Blood. 
2011;118(8):2351-2357. 
134. Viollier R, Socié G, Tichelli A, et al. Recent improvement in outcome of 
unrelated donor transplantation for aplastic anemia. Bone Marrow 
Transplantation. 2008;41(1):45-50. 
135. Bacigalupo A, Socie G, Hamladji RM, et al. Current outcome of HLA 
identical sibling versus unrelated donor transplants in severe aplastic 
anemia: an EBMT analysis. Haematologica. 2015;100(5):696-702. 
136. Bacigalupo A, Marsh JC. Unrelated donor search and unrelated donor 
transplantation in the adult aplastic anaemia patient aged 18-40 years 
without an HLA-identical sibling and failing immunosuppression. Bone 
Marrow Transplant. 2013;48(2):198-200. 
137. Dufour C, Veys P, Carraro E, et al. Similar outcome of upfront-unrelated 
and matched sibling stem cell transplantation in idiopathic paediatric 
aplastic anaemia. A study on behalf of the UK Paediatric BMT Working 
Party, Paediatric Diseases Working Party and Severe Aplastic Anaemia 
Working Party of EBMT. Br J Haematol. 2015;171(4):585-594. 
138. Eapen M, Le Rademacher J, Antin JH, et al. Effect of stem cell source on 
outcomes after unrelated donor transplantation in severe aplastic anemia. 
Blood. 2011;118(9):2618-2621. 
139. Samarasinghe S, Steward C, Hiwarkar P, et al. Excellent outcome of 
matched unrelated donor transplantation in paediatric aplastic anaemia 
following failure with immunosuppressive therapy: a United Kingdom 
multicentre retrospective experience. Br J Haematol. 2012;157(3):339-
346. 
 
47 
140. Peffault de Latour R. Transplantation for bone marrow failure- current 
issues. Hematology Am Soc Hematol Educ Program. 2016;2016(1):90-
98. 
141. Peffault de Latour R, Purtill D, Ruggeri A, et al. Influence of nucleated 
cell dose on overall survival of unrelated cord blood transplantation for 
patients with severe acquired aplastic anemia: a study by eurocord and the 
aplastic anemia working party of the European group for blood and 
marrow transplantation. Biol Blood Marrow Transplant. 2011;17(1):78-
85. 
142. Bacigalupo A, Giammarco S. Haploidentical donor transplants for severe 
aplastic anemia. Semin Hematol. 2019;56(3):190-193. 
143. Bacigalupo A. Alternative donor transplants for severe aplastic anemia. 
Hematology. 2018;2018(1):467-473. 
144. Ades L, Mary JY, Robin M, et al. Long-term outcome after bone marrow 
transplantation for severe aplastic anemia. Blood. 2004;103(7):2490-
2497. 
145. Deeg HJ, Leisenring W, Storb R, et al. Long-term outcome after marrow 
transplantation for severe aplastic anemia. Blood. 1998;91(10):3637-
3645. 
146. Konopacki J, Porcher R, Robin M, et al. Long-term follow up after 
allogeneic stem cell transplantation in patients with severe aplastic anemia 
after cyclophosphamide plus antithymocyte globulin conditioning. 
Haematologica. 2012;97(5):710-716. 
147. Frickhofen N, Kaltwasser JP, Schrezenmeier H, et al. Treatment of 
aplastic anemia with antilymphocyte globulin and methylprednisolone 
with or without cyclosporine. The German Aplastic Anemia Study Group. 
N Engl J Med. 1991;324(19):1297-1304. 
148. Bacigalupo A, Bruno B, Saracco P, et al. Antilymphocyte globulin, 
cyclosporine, prednisolone, and granulocyte colony-stimulating factor for 
severe aplastic anemia: an update of the GITMO/EBMT study on 100 
patients. European Group for Blood and Marrow Transplantation (EBMT) 
Working Party on Severe Aplastic Anemia and the Gruppo Italiano 
Trapianti di Midolio Osseo (GITMO). Blood. 2000;95(6):1931-1934. 
149. Kojima S, Hibi S, Kosaka Y, et al. Immunosuppressive therapy using 
antithymocyte globulin, cyclosporine, and danazol with or without human 
granulocyte colony-stimulating factor in children with acquired aplastic 
anemia. Blood. 2000;96(6):2049-2054. 
150. Führer M, Burdach S, Ebell W, et al. Relapse and clonal disease in 
children with aplastic anemia (AA) after immunosuppressive therapy 
(IST): the SAA 94 experience. German/Austrian Pediatric Aplastic 
Anemia Working Group. Klin Padiatr. 1998;210(4):173-179. 
151. Rosenfeld SJ, Kimball J, Vining D, Young NS. Intensive 
immunosuppression with antithymocyte globulin and cyclosporine as 
Aplastic anemia - a population-based study of epidemiology, treatment, and prognostic factors 
46 
cyclophosphamide, anti-thymocyte globulin and total body irradiation. Br 
J Haematol. 2001;114(3):706-711. 
129. Margolis D, Camitta B, Pietryga D, et al. Unrelated donor bone marrow 
transplantation to treat severe aplastic anaemia in children and young 
adults. Br J Haematol. 1996;94(1):65-72. 
130. Bacigalupo A, Socie G, Lanino E, et al. Fludarabine, cyclophosphamide, 
antithymocyte globulin, with or without low dose total body irradiation, 
for alternative donor transplants, in acquired severe aplastic anemia: a 
retrospective study from the EBMT-SAA Working Party. 
Haematologica. 2010;95(6):976-982. 
131. Socie G. Allogeneic BM transplantation for the treatment of aplastic 
anemia: current results and expanding donor possibilities. Hematology 
Am Soc Hematol Educ Program.2013; 2013(1):82-86. 
132. Maury S, Balere-Appert ML, Pollichieni S, et al. Outcome of patients 
activating an unrelated donor search for severe acquired aplastic anemia. 
Am J Hematol. 2013;88(10):868-873. 
133. Marsh JC, Gupta V, Lim Z, et al. Alemtuzumab with fludarabine and 
cyclophosphamide reduces chronic graft-versus-host disease after 
allogeneic stem cell transplantation for acquired aplastic anemia. Blood. 
2011;118(8):2351-2357. 
134. Viollier R, Socié G, Tichelli A, et al. Recent improvement in outcome of 
unrelated donor transplantation for aplastic anemia. Bone Marrow 
Transplantation. 2008;41(1):45-50. 
135. Bacigalupo A, Socie G, Hamladji RM, et al. Current outcome of HLA 
identical sibling versus unrelated donor transplants in severe aplastic 
anemia: an EBMT analysis. Haematologica. 2015;100(5):696-702. 
136. Bacigalupo A, Marsh JC. Unrelated donor search and unrelated donor 
transplantation in the adult aplastic anaemia patient aged 18-40 years 
without an HLA-identical sibling and failing immunosuppression. Bone 
Marrow Transplant. 2013;48(2):198-200. 
137. Dufour C, Veys P, Carraro E, et al. Similar outcome of upfront-unrelated 
and matched sibling stem cell transplantation in idiopathic paediatric 
aplastic anaemia. A study on behalf of the UK Paediatric BMT Working 
Party, Paediatric Diseases Working Party and Severe Aplastic Anaemia 
Working Party of EBMT. Br J Haematol. 2015;171(4):585-594. 
138. Eapen M, Le Rademacher J, Antin JH, et al. Effect of stem cell source on 
outcomes after unrelated donor transplantation in severe aplastic anemia. 
Blood. 2011;118(9):2618-2621. 
139. Samarasinghe S, Steward C, Hiwarkar P, et al. Excellent outcome of 
matched unrelated donor transplantation in paediatric aplastic anaemia 
following failure with immunosuppressive therapy: a United Kingdom 
multicentre retrospective experience. Br J Haematol. 2012;157(3):339-
346. 
 
47 
140. Peffault de Latour R. Transplantation for bone marrow failure- current 
issues. Hematology Am Soc Hematol Educ Program. 2016;2016(1):90-
98. 
141. Peffault de Latour R, Purtill D, Ruggeri A, et al. Influence of nucleated 
cell dose on overall survival of unrelated cord blood transplantation for 
patients with severe acquired aplastic anemia: a study by eurocord and the 
aplastic anemia working party of the European group for blood and 
marrow transplantation. Biol Blood Marrow Transplant. 2011;17(1):78-
85. 
142. Bacigalupo A, Giammarco S. Haploidentical donor transplants for severe 
aplastic anemia. Semin Hematol. 2019;56(3):190-193. 
143. Bacigalupo A. Alternative donor transplants for severe aplastic anemia. 
Hematology. 2018;2018(1):467-473. 
144. Ades L, Mary JY, Robin M, et al. Long-term outcome after bone marrow 
transplantation for severe aplastic anemia. Blood. 2004;103(7):2490-
2497. 
145. Deeg HJ, Leisenring W, Storb R, et al. Long-term outcome after marrow 
transplantation for severe aplastic anemia. Blood. 1998;91(10):3637-
3645. 
146. Konopacki J, Porcher R, Robin M, et al. Long-term follow up after 
allogeneic stem cell transplantation in patients with severe aplastic anemia 
after cyclophosphamide plus antithymocyte globulin conditioning. 
Haematologica. 2012;97(5):710-716. 
147. Frickhofen N, Kaltwasser JP, Schrezenmeier H, et al. Treatment of 
aplastic anemia with antilymphocyte globulin and methylprednisolone 
with or without cyclosporine. The German Aplastic Anemia Study Group. 
N Engl J Med. 1991;324(19):1297-1304. 
148. Bacigalupo A, Bruno B, Saracco P, et al. Antilymphocyte globulin, 
cyclosporine, prednisolone, and granulocyte colony-stimulating factor for 
severe aplastic anemia: an update of the GITMO/EBMT study on 100 
patients. European Group for Blood and Marrow Transplantation (EBMT) 
Working Party on Severe Aplastic Anemia and the Gruppo Italiano 
Trapianti di Midolio Osseo (GITMO). Blood. 2000;95(6):1931-1934. 
149. Kojima S, Hibi S, Kosaka Y, et al. Immunosuppressive therapy using 
antithymocyte globulin, cyclosporine, and danazol with or without human 
granulocyte colony-stimulating factor in children with acquired aplastic 
anemia. Blood. 2000;96(6):2049-2054. 
150. Führer M, Burdach S, Ebell W, et al. Relapse and clonal disease in 
children with aplastic anemia (AA) after immunosuppressive therapy 
(IST): the SAA 94 experience. German/Austrian Pediatric Aplastic 
Anemia Working Group. Klin Padiatr. 1998;210(4):173-179. 
151. Rosenfeld SJ, Kimball J, Vining D, Young NS. Intensive 
immunosuppression with antithymocyte globulin and cyclosporine as 
Aplastic anemia - a population-based study of epidemiology, treatment, and prognostic factors 
48 
treatment for severe acquired aplastic anemia. Blood. 1995;85(11):3058-
3065. 
152. Scheinberg P, Nunez O, Wu C, Young NS. Treatment of severe aplastic 
anaemia with combined immunosuppression: anti-thymocyte globulin, 
ciclosporin and mycophenolate mofetil. Br J Haematol. 2006;133(6):606-
611. 
153. Scheinberg P, Wu CO, Nunez O, et al. Treatment of severe aplastic 
anemia with a combination of horse antithymocyte globulin and 
cyclosporine, with or without sirolimus: a prospective randomized study. 
Haematologica. 2009;94(3):348-354. 
154. Scheinberg P, Nunez O, Weinstein B, Scheinberg P, Wu CO, Young NS. 
Activity of alemtuzumab monotherapy in treatment-naive, relapsed, and 
refractory severe acquired aplastic anemia. Blood. 2012;119(2):345-354. 
155. Brodsky RA, Chen AR, Brodsky I, Jones RJ. High-dose 
cyclophosphamide as salvage therapy for severe aplastic anemia. Exp 
Hematol. 2004;32(5):435-440. 
156. Marsh JC, Ball SE, Cavenagh J, et al. Guidelines for the diagnosis and 
management of aplastic anaemia. Br J Haematol. 2009;147(1):43-70. 
157. Scheinberg P, Nunez O, Weinstein B, et al. Horse versus rabbit 
antithymocyte globulin in acquired aplastic anemia. N Engl J Med. 
2011;365(5):430-438. 
158. Afable MG, Shaik M, Sugimoto Y, et al. Efficacy of rabbit anti-thymocyte 
globulin in severe aplastic anemia. Haematologica. 2011;96(9):1269-
1275. 
159. Atta EH, Dias DS, Marra VL, de Azevedo AM. Comparison between 
horse and rabbit antithymocyte globulin as first-line treatment for patients 
with severe aplastic anemia: a single-center retrospective study. Ann 
Hematol. 2010;89(9):851-859. 
160. Zheng Y, Liu Y, Chu Y. Immunosuppressive therapy for acquired severe 
aplastic anemia (SAA): a prospective comparison of four different 
regimens. Exp Hematol. 2006;34(7):826-831. 
161. Vallejo C, Montesinos P, Polo M, et al. Rabbit antithymocyte globulin 
versus horse antithymocyte globulin for treatment of acquired aplastic 
anemia: a retrospective analysis. Ann Hematol. 2015;94(6):947-954. 
162. Peffault de Latour R, Tabrizi R, Marcais A, et al. Nationwide survey on 
the use of horse antithymocyte globulins (ATGAM) in patients with 
acquired aplastic anemia: A report on behalf of the French Reference 
Center for Aplastic Anemia. Am J Hematol. 2018;93(5):635-642. 
163. Marsh JC, Bacigalupo A, Schrezenmeier H, et al. Prospective study of 
rabbit antithymocyte globulin and cyclosporine for aplastic anemia from 
the EBMT Severe Aplastic Anaemia Working Party. Blood. 
2012;119(23):5391-5396. 
 
49 
164. Tichelli A, Socie G, Henry-Amar M, et al. Effectiveness of 
immunosuppressive therapy in older patients with aplastic anemia. 
European Group for Blood and Marrow Transplantation Severe Aplastic 
Anaemia Working Party. Ann Intern Med. 1999;130(3):193-201. 
165. Bacigalupo A, Oneto R, Schrezenmeier H, et al. First line treatment of 
aplastic anemia with thymoglobuline in Europe and Asia: Outcome of 955 
patients treated 2001-2012. American Journal of Hematology. 
2018;93(5):643-648. 
166. Yoshida N, Kobayashi R, Yabe H, et al. First-line treatment for severe 
aplastic anemia in children: bone marrow transplantation from a matched 
family donor versus immunosuppressive therapy. Haematologica. 
2014;99(12):1784-1791. 
167. Rogers ZR, Nakano TA, Olson TS, et al. Immunosuppressive therapy for 
pediatric aplastic anemia: a North American Pediatric Aplastic Anemia 
Consortium study. Haematologica. 2019;104(10):1974-1983. 
168. Dufour C, Pillon M, Socie G, et al. Outcome of aplastic anaemia in 
children. A study by the severe aplastic anaemia and paediatric disease 
working parties of the European group blood and bone marrow transplant. 
Br J Haematol. 2015;169(4):565-573. 
169. Marsh J, Schrezenmeier H, Marin P, et al. Prospective randomized 
multicenter study comparing cyclosporin alone versus the combination of 
antithymocyte globulin and cyclosporin for treatment of patients with 
nonsevere aplastic anemia: a report from the European Blood and Marrow 
Transplant (EBMT) Severe Aplastic Anaemia Working Party. Blood. 
1999;93(7):2191-2195. 
170. Scheinberg P, Wu CO, Nunez O, Young NS. Predicting response to 
immunosuppressive therapy and survival in severe aplastic anaemia. Br J 
Haematol. 2009;144(2):206-216. 
171. Atta EH, Lima CBL, Dias DSP, et al. Predictors of early mortality after 
rabbit antithymocyte globulin as first-line treatment in severe aplastic 
anemia. Ann Hematol. 2017;96(11):1907-1914. 
172. Fuhrer M, Rampf U, Baumann I, et al. Immunosuppressive therapy for 
aplastic anemia in children: a more severe disease predicts better survival. 
Blood. 2005;106(6):2102-2104. 
173. Tichelli A, Schrezenmeier H, Socié G, et al. A randomized controlled 
study in patients with newly diagnosed severe aplastic anemia receiving 
antithymocyte globulin (ATG), cyclosporine, with or without G-CSF: a 
study of the SAA Working Party of the European Group for Blood and 
Marrow Transplantation. Blood. 2011;117(17):4434-4441. 
174. Schrezenmeier H, Marin P, Raghavachar A, et al. Relapse of aplastic 
anaemia after immunosuppressive treatment: a report from the European 
Bone Marrow Transplantation Group SAA Working Party. Br J 
Haematol. 1993;85(2):371-377. 
Aplastic anemia - a population-based study of epidemiology, treatment, and prognostic factors 
48 
treatment for severe acquired aplastic anemia. Blood. 1995;85(11):3058-
3065. 
152. Scheinberg P, Nunez O, Wu C, Young NS. Treatment of severe aplastic 
anaemia with combined immunosuppression: anti-thymocyte globulin, 
ciclosporin and mycophenolate mofetil. Br J Haematol. 2006;133(6):606-
611. 
153. Scheinberg P, Wu CO, Nunez O, et al. Treatment of severe aplastic 
anemia with a combination of horse antithymocyte globulin and 
cyclosporine, with or without sirolimus: a prospective randomized study. 
Haematologica. 2009;94(3):348-354. 
154. Scheinberg P, Nunez O, Weinstein B, Scheinberg P, Wu CO, Young NS. 
Activity of alemtuzumab monotherapy in treatment-naive, relapsed, and 
refractory severe acquired aplastic anemia. Blood. 2012;119(2):345-354. 
155. Brodsky RA, Chen AR, Brodsky I, Jones RJ. High-dose 
cyclophosphamide as salvage therapy for severe aplastic anemia. Exp 
Hematol. 2004;32(5):435-440. 
156. Marsh JC, Ball SE, Cavenagh J, et al. Guidelines for the diagnosis and 
management of aplastic anaemia. Br J Haematol. 2009;147(1):43-70. 
157. Scheinberg P, Nunez O, Weinstein B, et al. Horse versus rabbit 
antithymocyte globulin in acquired aplastic anemia. N Engl J Med. 
2011;365(5):430-438. 
158. Afable MG, Shaik M, Sugimoto Y, et al. Efficacy of rabbit anti-thymocyte 
globulin in severe aplastic anemia. Haematologica. 2011;96(9):1269-
1275. 
159. Atta EH, Dias DS, Marra VL, de Azevedo AM. Comparison between 
horse and rabbit antithymocyte globulin as first-line treatment for patients 
with severe aplastic anemia: a single-center retrospective study. Ann 
Hematol. 2010;89(9):851-859. 
160. Zheng Y, Liu Y, Chu Y. Immunosuppressive therapy for acquired severe 
aplastic anemia (SAA): a prospective comparison of four different 
regimens. Exp Hematol. 2006;34(7):826-831. 
161. Vallejo C, Montesinos P, Polo M, et al. Rabbit antithymocyte globulin 
versus horse antithymocyte globulin for treatment of acquired aplastic 
anemia: a retrospective analysis. Ann Hematol. 2015;94(6):947-954. 
162. Peffault de Latour R, Tabrizi R, Marcais A, et al. Nationwide survey on 
the use of horse antithymocyte globulins (ATGAM) in patients with 
acquired aplastic anemia: A report on behalf of the French Reference 
Center for Aplastic Anemia. Am J Hematol. 2018;93(5):635-642. 
163. Marsh JC, Bacigalupo A, Schrezenmeier H, et al. Prospective study of 
rabbit antithymocyte globulin and cyclosporine for aplastic anemia from 
the EBMT Severe Aplastic Anaemia Working Party. Blood. 
2012;119(23):5391-5396. 
 
49 
164. Tichelli A, Socie G, Henry-Amar M, et al. Effectiveness of 
immunosuppressive therapy in older patients with aplastic anemia. 
European Group for Blood and Marrow Transplantation Severe Aplastic 
Anaemia Working Party. Ann Intern Med. 1999;130(3):193-201. 
165. Bacigalupo A, Oneto R, Schrezenmeier H, et al. First line treatment of 
aplastic anemia with thymoglobuline in Europe and Asia: Outcome of 955 
patients treated 2001-2012. American Journal of Hematology. 
2018;93(5):643-648. 
166. Yoshida N, Kobayashi R, Yabe H, et al. First-line treatment for severe 
aplastic anemia in children: bone marrow transplantation from a matched 
family donor versus immunosuppressive therapy. Haematologica. 
2014;99(12):1784-1791. 
167. Rogers ZR, Nakano TA, Olson TS, et al. Immunosuppressive therapy for 
pediatric aplastic anemia: a North American Pediatric Aplastic Anemia 
Consortium study. Haematologica. 2019;104(10):1974-1983. 
168. Dufour C, Pillon M, Socie G, et al. Outcome of aplastic anaemia in 
children. A study by the severe aplastic anaemia and paediatric disease 
working parties of the European group blood and bone marrow transplant. 
Br J Haematol. 2015;169(4):565-573. 
169. Marsh J, Schrezenmeier H, Marin P, et al. Prospective randomized 
multicenter study comparing cyclosporin alone versus the combination of 
antithymocyte globulin and cyclosporin for treatment of patients with 
nonsevere aplastic anemia: a report from the European Blood and Marrow 
Transplant (EBMT) Severe Aplastic Anaemia Working Party. Blood. 
1999;93(7):2191-2195. 
170. Scheinberg P, Wu CO, Nunez O, Young NS. Predicting response to 
immunosuppressive therapy and survival in severe aplastic anaemia. Br J 
Haematol. 2009;144(2):206-216. 
171. Atta EH, Lima CBL, Dias DSP, et al. Predictors of early mortality after 
rabbit antithymocyte globulin as first-line treatment in severe aplastic 
anemia. Ann Hematol. 2017;96(11):1907-1914. 
172. Fuhrer M, Rampf U, Baumann I, et al. Immunosuppressive therapy for 
aplastic anemia in children: a more severe disease predicts better survival. 
Blood. 2005;106(6):2102-2104. 
173. Tichelli A, Schrezenmeier H, Socié G, et al. A randomized controlled 
study in patients with newly diagnosed severe aplastic anemia receiving 
antithymocyte globulin (ATG), cyclosporine, with or without G-CSF: a 
study of the SAA Working Party of the European Group for Blood and 
Marrow Transplantation. Blood. 2011;117(17):4434-4441. 
174. Schrezenmeier H, Marin P, Raghavachar A, et al. Relapse of aplastic 
anaemia after immunosuppressive treatment: a report from the European 
Bone Marrow Transplantation Group SAA Working Party. Br J 
Haematol. 1993;85(2):371-377. 
Aplastic anemia - a population-based study of epidemiology, treatment, and prognostic factors 
50 
175. Scheinberg P, Nunez O, Young NS. Retreatment with rabbit anti-
thymocyte globulin and ciclosporin for patients with relapsed or 
refractory severe aplastic anaemia. Br J Haematol. 2006;133(6):622-627. 
176. Means R, Krantz S, Dessypris E, et al. Re-treatment of aplastic anemia 
with antithymocyte globulin or antilymphocyte serum. The American 
Journal of Medicine. 1988;84:678-682. 
177. Scheinberg P, Townsley D, Dumitriu B, et al. Horse antithymocyte 
globulin as salvage therapy after rabbit antithymocyte globulin for severe 
aplastic anemia. Am J Hematol. 2014;89(5):467-469. 
178. Gupta V, Gordon-Smith EC, Cook G, et al. A third course of anti-
thymocyte globulin in aplastic anaemia is only beneficial in previous 
responders. Br J Haematol. 2005;129(1):110-117. 
179. Di Bona E, F. Rodeghiero, B. Bruno, A. Gabbas, P. Foa, A. Locasciulli, 
C. Rosanelli, L. Camba, P. Saracco, A. Lippi, A. P. Iori, F. Porta, V. De 
Rossi, B. Comotti, P. Iacopino, C. Dufour and A. Bacigalupo for the 
Gruppo Italiano Trapianto di Midollo Osseo (GITMO). Rabbit 
antithymocyte globulin (r-ATG) plus cyclosporine and granulocyte 
colony stimulating factor is an effective treatment for aplastic anaemia 
patients unresponsive to a first course of intensive immunosuppressive 
therapy. British Journal of Haematology. 1999(107):330-334. 
180. Marsh JC, Kulasekararaj AG. Management of the refractory aplastic 
anemia patient: what are the options? Hematology Am Soc Hematol Educ 
Program. 2013;2013:87-94. 
181. Scheinberg P, Young NS. How I treat acquired aplastic anemia. Blood. 
2012;120(6):1185-1196. 
182. Valdez JM, Scheinberg P, Nunez O, Wu CO, Young NS, Walsh TJ. 
Decreased infection-related mortality and improved survival in severe 
aplastic anemia in the past two decades. Clin Infect Dis. 2011;52(6):726-
735. 
183. Olnes MJ, Scheinberg P, Calvo KR, et al. Eltrombopag and improved 
hematopoiesis in refractory aplastic anemia. N Engl J Med. 
2012;367(1):11-19. 
184. Desmond R, Townsley DM, Dumitriu B, et al. Eltrombopag restores 
trilineage hematopoiesis in refractory severe aplastic anemia that can be 
sustained on discontinuation of drug. Blood. 2014;123(12):1818-1825. 
185. Winkler T, Fan X, Cooper J, et al. Treatment optimization and genomic 
outcomes in refractory severe aplastic anemia treated with eltrombopag. 
Blood. 2019;133(24):2575-2585. 
186. Townsley DM, Scheinberg P, Winkler T, et al. Eltrombopag Added to 
Standard Immunosuppression for Aplastic Anemia. N Engl J Med. 
2017;376(16):1540-1550. 
187. Szklo M. Population-based cohort studies. Epidemiol Rev. 1998;20(1):81-
90. 
 
51 
188. Clausen N, Kreuger A, Salmi T, Storm-Mathisen I, Johannesson G. 
Severe aplastic anaemia in the Nordic countries: a population based study 
of incidence, presentation, course, and outcome. Arch Dis Child. 
1996;74(4):319-322. 
189. Pulsipher MA, Young NS, Tolar J, et al. Optimization of therapy for 
severe aplastic anemia based on clinical, biologic, and treatment response 
parameters: conclusions of an international working group on severe 
aplastic anemia convened by the Blood and Marrow Transplant Clinical 
Trials Network, March 2010. Biol Blood Marrow Transplant. 
2011;17(3):291-299. 
190. Marsh JC, Bacigalupo A, Schrezenmeier H, et al. Prospective study of 
rabbit antithymocyte globulin and cyclosporine for aplastic anemia from 
the EBMT Severe Aplastic Anaemia Working Party. Blood. 
2012;119(23):5391-5396. 
191. Shi J, Ge M, Lu S, et al. Intrinsic impairment of CD4(+)CD25(+) 
regulatory T cells in acquired aplastic anemia. Blood. 2012;120(8):1624-
1632. 
192. Solomou EE, Rezvani K, Mielke S, et al. Deficient CD4+ CD25+ 
FOXP3+ T regulatory cells in acquired aplastic anemia. Blood. 
2007;110(5):1603-1606. 
193. McCabe A, Smith JNP, Costello A, Maloney J, Katikaneni D, 
MacNamara KC. Hematopoietic stem cell loss and hematopoietic failure 
in severe aplastic anemia is driven by macrophages and aberrant 
podoplanin expression. Haematologica. 2018;103(9):1451-1461. 
194. Gomez-Almaguer D, Vazquez-Mellado A, Navarro-Cabrera JR, et al. The 
Latin American experience of allografting patients with severe aplastic 
anaemia: real-world data on the impact of stem cell source and ATG 
administration in HLA-identical sibling transplants. Bone Marrow 
Transplant. 2017;52(1):41-46. 
195. Sugita J. HLA-haploidentical stem cell transplantation using 
posttransplant cyclophosphamide. Int J Hematol. 2019;110(1):30-38. 
 
Aplastic anemia - a population-based study of epidemiology, treatment, and prognostic factors 
50 
175. Scheinberg P, Nunez O, Young NS. Retreatment with rabbit anti-
thymocyte globulin and ciclosporin for patients with relapsed or 
refractory severe aplastic anaemia. Br J Haematol. 2006;133(6):622-627. 
176. Means R, Krantz S, Dessypris E, et al. Re-treatment of aplastic anemia 
with antithymocyte globulin or antilymphocyte serum. The American 
Journal of Medicine. 1988;84:678-682. 
177. Scheinberg P, Townsley D, Dumitriu B, et al. Horse antithymocyte 
globulin as salvage therapy after rabbit antithymocyte globulin for severe 
aplastic anemia. Am J Hematol. 2014;89(5):467-469. 
178. Gupta V, Gordon-Smith EC, Cook G, et al. A third course of anti-
thymocyte globulin in aplastic anaemia is only beneficial in previous 
responders. Br J Haematol. 2005;129(1):110-117. 
179. Di Bona E, F. Rodeghiero, B. Bruno, A. Gabbas, P. Foa, A. Locasciulli, 
C. Rosanelli, L. Camba, P. Saracco, A. Lippi, A. P. Iori, F. Porta, V. De 
Rossi, B. Comotti, P. Iacopino, C. Dufour and A. Bacigalupo for the 
Gruppo Italiano Trapianto di Midollo Osseo (GITMO). Rabbit 
antithymocyte globulin (r-ATG) plus cyclosporine and granulocyte 
colony stimulating factor is an effective treatment for aplastic anaemia 
patients unresponsive to a first course of intensive immunosuppressive 
therapy. British Journal of Haematology. 1999(107):330-334. 
180. Marsh JC, Kulasekararaj AG. Management of the refractory aplastic 
anemia patient: what are the options? Hematology Am Soc Hematol Educ 
Program. 2013;2013:87-94. 
181. Scheinberg P, Young NS. How I treat acquired aplastic anemia. Blood. 
2012;120(6):1185-1196. 
182. Valdez JM, Scheinberg P, Nunez O, Wu CO, Young NS, Walsh TJ. 
Decreased infection-related mortality and improved survival in severe 
aplastic anemia in the past two decades. Clin Infect Dis. 2011;52(6):726-
735. 
183. Olnes MJ, Scheinberg P, Calvo KR, et al. Eltrombopag and improved 
hematopoiesis in refractory aplastic anemia. N Engl J Med. 
2012;367(1):11-19. 
184. Desmond R, Townsley DM, Dumitriu B, et al. Eltrombopag restores 
trilineage hematopoiesis in refractory severe aplastic anemia that can be 
sustained on discontinuation of drug. Blood. 2014;123(12):1818-1825. 
185. Winkler T, Fan X, Cooper J, et al. Treatment optimization and genomic 
outcomes in refractory severe aplastic anemia treated with eltrombopag. 
Blood. 2019;133(24):2575-2585. 
186. Townsley DM, Scheinberg P, Winkler T, et al. Eltrombopag Added to 
Standard Immunosuppression for Aplastic Anemia. N Engl J Med. 
2017;376(16):1540-1550. 
187. Szklo M. Population-based cohort studies. Epidemiol Rev. 1998;20(1):81-
90. 
 
51 
188. Clausen N, Kreuger A, Salmi T, Storm-Mathisen I, Johannesson G. 
Severe aplastic anaemia in the Nordic countries: a population based study 
of incidence, presentation, course, and outcome. Arch Dis Child. 
1996;74(4):319-322. 
189. Pulsipher MA, Young NS, Tolar J, et al. Optimization of therapy for 
severe aplastic anemia based on clinical, biologic, and treatment response 
parameters: conclusions of an international working group on severe 
aplastic anemia convened by the Blood and Marrow Transplant Clinical 
Trials Network, March 2010. Biol Blood Marrow Transplant. 
2011;17(3):291-299. 
190. Marsh JC, Bacigalupo A, Schrezenmeier H, et al. Prospective study of 
rabbit antithymocyte globulin and cyclosporine for aplastic anemia from 
the EBMT Severe Aplastic Anaemia Working Party. Blood. 
2012;119(23):5391-5396. 
191. Shi J, Ge M, Lu S, et al. Intrinsic impairment of CD4(+)CD25(+) 
regulatory T cells in acquired aplastic anemia. Blood. 2012;120(8):1624-
1632. 
192. Solomou EE, Rezvani K, Mielke S, et al. Deficient CD4+ CD25+ 
FOXP3+ T regulatory cells in acquired aplastic anemia. Blood. 
2007;110(5):1603-1606. 
193. McCabe A, Smith JNP, Costello A, Maloney J, Katikaneni D, 
MacNamara KC. Hematopoietic stem cell loss and hematopoietic failure 
in severe aplastic anemia is driven by macrophages and aberrant 
podoplanin expression. Haematologica. 2018;103(9):1451-1461. 
194. Gomez-Almaguer D, Vazquez-Mellado A, Navarro-Cabrera JR, et al. The 
Latin American experience of allografting patients with severe aplastic 
anaemia: real-world data on the impact of stem cell source and ATG 
administration in HLA-identical sibling transplants. Bone Marrow 
Transplant. 2017;52(1):41-46. 
195. Sugita J. HLA-haploidentical stem cell transplantation using 
posttransplant cyclophosphamide. Int J Hematol. 2019;110(1):30-38. 
 
